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MESSAGE FROM DIRECTOR 
 
Dr Lorenzo Savioli  
Director, Department of Control of Neglected Tropical Diseases  
 
 
Neglected tropical diseases have afflicted humanity since time immemorial. 
Today, neglected tropical diseases are a symptom of poverty and disadvantage.  
Those most affected are the poorest populations often living in remote, rural areas, 
urban slums or in conflict zones. With little political voice, neglected tropical diseases 
have a low profile and status in public health priorities. Stigma attached to these 
diseases has hampered efforts to bring them out of the shadows.  
 
Conditions of poverty perpetuate these diseases, while the health impact of these 
diseases perpetuates poverty.  
 
Our challenges are great, but so is our determination to work together to find solutions 
and achieve results. The year of 2006 witnessed important achievements in the history 
of the fight against neglected tropical diseases. 
 
First, a major step was to view neglected tropical diseases as a group.  
WHO and its partners developed a conceptual framework to move away from a purely 
disease-centred approach to an integrated one tackling selected neglected tropical 
diseases as a group.  
WHO has taken this agenda forward promoting a three pronged approach: broader 
coverage with rapid-impact interventions (especially against helminth 
infections), strengthened vector control to reduce transmission of several diseases, and 
improved surveillance and high-quality care of diseases such as buruli ulcer, Chagas 
disease, leishmaniasis and sleeping sickness. WHO also addresses the particularities 
and obstacles of neglected tropical disease control in humanitarian emergencies, where 
mortality and morbidity are higher than usual. Research and development, including 
operational research, underpin activities in all areas.  
When these diseases are viewed together, we gain critical mass. We get a better grip on 
the scale of the economic and social as well as the health burdens. As yet another 
advantage, grouping these diseases together creates opportunities for the sharing of 
innovative solutions, especially as most control programmes face similar operational 
constraints. 
Second is the availability of safe and highly effective drugs – the best drugs the world 
can offer. In a most welcome trend, public-private partnerships have formed to combat 
these diseases. Some of these partnership agreements provide for the donation of drugs 
wherever needed, in whatever quantity, as long as it takes to reach targets. 
Evidence has shown that a package of a few anthelminthic drugs is able to bring relief 
for over 15 types of helminthic and parasitic infections. Available drugs are so safe and 
effective that they can be administered pre-emptively to almost all at-risk populations. 
 
As the most recent step forward, WHO has developed strategies for the integrated 
delivery of interventions for several overlapping diseases. Since neglected tropical 
diseases frequently cluster geographically and overlap, systems created to deliver one 
intervention can be used to deliver others.  
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While important constraints remain, the prospects for controlling some of the most 
burdensome neglected diseases, on a large scale and in sustainable ways, have never 
looked better. 
 
We now need to urgently work together with endemic countries and the international 
community to improve neglected communities’ access to the rapid-impact interventions 
and quality care to protect them from neglected tropical diseases and to ensure their 
human and social development. The need to do so is incontestable from all perspectives: 
moral, human rights, economic and global public good.  
 
The first WHO annual report on NTDs highlights the high burden and socio economic 
impact of these diseases in the world. More importantly, it shows the magnitude of the 
efforts undertaken by thousands dedicated workers, communities and partners in fighting 
disease and poverty. The achievements are so impressive that they deserve to be widely 
publicized. Challenges are enormous, but so is our commitment to make NTDs history.  
  
 4 
ACKNOWLEDGEMENTS 
 
 
 
The annual report is the result of hard work and dedication of people from different parts 
of the world.  
Achievements made were possible thanks to health ministries of member countries, 
partners, pharmaceutical companies, donors, non-governmental organizations, experts 
in neglected tropical diseases and WHO colleagues in countries and regional offices. 
 
Special thanks are extended to those who contributed to development of this document. 
  
 5 
HIGHLIGHT IN 2006  
 
 
 
Worldwide coverage and potential 
 
By January 2006, 57 million school children and 48 million pre-school children treated for 
soil-transmitted helminthiasis.  
 
More than 220 000 people were benefited from Multi drug therapy against leprosy free of 
charge  
 
100% of sleeping sickness patients were treated free of charge in 18 endemic countries 
 
In May, Executive Board of WHO launched the first resolution for the control of 
leishmaniasis, EB 118. R3.  
 
 
Local success 
 
India declared elimination of yaws 
 
Sri Lanka completed five rounds of mass drug administration against lymphatic filariasis 
protecting 9.8 million people at risk  
 
Mass drug administration against lymphatic filariasis dropped prevalence rate of the 
disease below 1% achieving interruption of transmission in the United Republic of 
Tanzania 
 
French Polynesia completed 7th round of mass drug administration again lymphatic 
filariasis reaching 97% of the whole population.  
 
Co-administration of albendazole, ivermectin and praziquantel for the respective 
treatment of soil-transmitted helminthiasis, lymphatic filariasis/onchocerciasis and 
schistosomiasis was safely and successfully introduced into national control 
programmes in Zanzibar and Nigeria. 
 
Bhutan and the Maldives surpassed the target of 75% coverage of the at risk 
populations of soil-transmitted helminthiasis. 
 
More than 75% of the at risk populations were treated for both soil-transmitted 
helminthiasis and schistosomiasis in Burkina Faso and Cambodia.  
 
Cambodia, Egypt and Morocco reduced the levels of schistosomiasis prevalence such 
that it is no longer considered a public health problem. 
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Meeting  
 
In December 2006, the department convened a global meeting to review progress 
towards meeting the target of the WHA resolution 54.19 on deworming people at risk of 
morbidity due to schistosomiasis and soil-transmitted helminthiasis. 
 
On 25-26 September 2006 the 5th Global Collaboration for Development of Pesticides 
for Public Health (GCDPP) took place to propose the foundation and strategies for WHO 
strengthening of its support to Member States on sound management of pesticides.  
 
 
Key publication  
 
In March 2006, several key documents were published including 'Guidelines for testing 
mosquito adulticides for indoor residual spraying and treatment of mosquito nets' that 
serves as a reference document for national programmes. 
 
In October a manual for health professional and programme managers, 'Preventive 
chemotherapy in Human Helminthiasis', was launched to guide the coordinated 
implementation of regular, systematic, large/scale interventions.  
 
 
Partnership  
 
On 6 February 2006, the Foundation for Innovative New Diagnostics (FIND) and the 
World Health Organization (WHO) signed Memorandum of Understanding for the 
development and evaluation of new diagnostic tests for human African trypanosomiasis 
with a grant from the Bill & Melinda Gates Foundation.  
 
Related to control of vector born diseases, the WHO Pesticide Evaluation Scheme 
(WHOPES) finalized the testing and evaluation of 5 pesticide products for public health 
use and developed, in collaboration with FAO, quality standards for 11 public health 
pesticide products. 
 
NTD further expanded its collaboration with FAO and UNEP on issues related to 
management of public health pesticides and prepared groundwork for Memorandum of 
Understanding with FAO.  
 
On 10 October 2006 sanofi-aventis signed a five year agreement to support the fight 
against human African trypanosomiasis, leishmaniasis, buruli ulcer and Chagas disease 
donating a total of US$ 25 million.  
 
In November 2006, Novartis agreed to donate 600 000 tables of triclabendazole for 
fascioliasis to WHO for the period of 2007-2009. 
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PART 1. MAGNITUDE OF NEGLECTED TROPICAL DISEASES  
 
 
Neglected tropical diseases have afflicted humanity since time immemorial and, in their 
long histories, have acquired notoriety as disabling and deforming diseases. In the past, 
their serious impact on health and productivity led to considerable knowledge about the 
diseases, and effective control tools were developed for many. In addition, as living 
conditions improved, opportunities for transmission were drastically reduced. As a result, 
these diseases are now rarely seen in populations that enjoy good access to health 
services and a reasonable standard of living. 
 
These diseases flourish in areas where water supply and sanitation are inadequate, 
nutrition is poor, literacy rates are low, health systems are rudimentary, and insects and 
other disease vectors are constant household and occupational companions. Not 
surprisingly, these diseases cluster together and frequently overlap wherever such 
conditions occur. In fact, the link with poverty is so strong that the prevalence of these 
diseases can serve as a proxy indicator of the level of a country’s socioeconomic 
development. 
 
100% of low-income countries are affected by at least five neglected tropical diseases 
simultaneously. 
Neglected tropical diseases are a devastating obstacle to human settlement and 
socioeconomic development of already impoverished countries.  
 
Figure 1. Countries affected by neglected tropical diseases by income group 
 
 
 
At least 1 billion people – one-sixth of the world population – currently suffer from one or 
more of these diseases.  
More than 40 million people are permanently incapacitated and disfigured by lymphatic 
filariasis. In Africa alone, schistosomiasis affects at least 160 million people. Of these, at 
least 30 million suffer permanent, life-threatening complications. 
 
Most neglected tropical diseases cause immense suffering and often life-long disabilities 
but rarely kill.  Therefore,  they do not receive the attention and funding of high-mortality 
diseases like AIDS, tuberculosis, and malaria. 
However, the price of neglect is too high; neglected tropical diseases have 
consequences for affected individuals, families and entire communities in terms of 
burden of disease, quality of life, loss of productivity and aggravation of poverty. 
 
Neglected diseases impose an enormous economic burden in terms of lost productivity 
and the high costs of long-term care. Occurring as they do in rural areas, they can 
jeopardize food security and cause dramatic changes in patterns of land use. When 
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surgery is required for treatment or rehabilitation, the costs are often beyond the reach of 
endemic countries. The disabled remain disabled, often in their youth. 
 
Neglected diseases can help guarantee that the next generation remains anchored in 
poverty. Schistosomiasis and guinea worm disease have a significant negative impact 
on school attendance. Sleeping sickness can permanently impair mental functions, and 
may cause mental retardation, even in children who are cured. Buruli ulcer takes its 
heaviest toll in lost limbs and crippling deformities in the young. 
 
For a large group of these diseases such as leprosy, filariasis, onchocerciasis,  trachoma, 
schistosomiasis and soil-transmitted helminthiasis and yaws effective, inexpensive or 
donated drugs are available for their prevention and control. These tools, when used on 
a large scale, are able to wipe out the burden caused by these ancient scourges of 
humanity. Large-scale, regular treatment plays a central role in the control of helminthic 
infections. For example, preventive chemotherapy against intestinal worms reduces 
mortality and morbidity in preschool children, improves the nutritional status and 
academic performance of schoolchildren, and improves the health and well-being of 
pregnant women and their babies. 
 
There is second group of NTDs for which the only clinical option currently available is 
systematic case-finding and management at an early stage. These diseases include 
Buruli ulcer, Chagas disease, cholera and other diarrhoeal diseases, human African 
trypanosomiasis and leishmaniasis. Simple diagnostic tools and safe and effective 
treatment regimens need to be developed urgently for some of these diseases. However, 
even for these infections, systematic use of the present, imperfect tools at an early stage 
can dramatically reduce mortality and morbidity. For others, vector control tools are 
available and present the main method of transmission control, as in the case of Chagas 
disease. 
 
Although medically diverse, neglected tropical diseases share several characteristics. 
They are almost exclusively concentrated in populations of the poor and powerless. 
Moreover, neglected diseases frequently exist, and often overlap, in remote rural areas 
or urban slums which even the most rudimentary health services fail to reach. 
 
Map 1. Overlapping threats to neglected populations 
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Neglect of these diseases occurs at three main levels. At the national level, these 
diseases are hidden in remote areas and are poorly documented. 
They are hidden for a second reason: stigma. Stigma keeps people –especially women 
– out of sight. It also discourages people from seeking care early in the disease course, 
when the chances of cure are greatest. 
Second, neglected diseases lack visibility at the international level. Tied as they are to 
specific geographical and environmental conditions, they do not travel. They impair or 
permanently disable millions of people, but cause comparatively few deaths. 
Third, these diseases have long been neglected by research and development. Industry 
has little incentive to develop drugs and vaccines for markets that cannot pay. 
When inexpensive and effective drugs already exist and are available, delivery fails 
because patients cannot pay and because health systems are weak or non-existent 
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PART 2. WHO ACTIVITIES AND ACHIEVEMENTS 
 
 
The year saw the launch of synergistic strategies, whereby neglected tropical diseases 
with similar operational demands are now being tackled in an integrated way. 
WHO has developed the conceptual framework moving from a purely disease centred 
approach to an integrated once tackling some neglected tropical diseases as a group 
launching the new Department of Control of Neglected Tropical Diseases (WHO/NTD). 
This makes practical sense in operational and strategic terms. 
WHO NTD strengthened its staffing at HQ and further invested in promotion of IVM and 
through close collaboration and support to several WHO Regions on inter-country and 
country-specific activities. 
 
Associated as they are with extreme poverty, these diseases share common 
determinants and must overcome similar obstacles to control. It thus makes sense, in an 
action-based strategy, to group the diseases according to shared operational and 
programmatic needs.  
Preventive chemotherapy is at the heart of this new strategy, which was launched with 
the support of more than 25 partner organizations. A package of just a few anthelminthic 
drugs – albendazole or/and mebendazole, praziquantel, ivermectin or 
diethylcarbamazine – is able to bring relief for over 15 types of helminthic and parasitic 
infections. Some of these drugs are donated on a large scale by the pharmaceutical 
industries and therefore widely accessible.  
 
Low-cost and innovative delivery systems have also been devised. The new streamlined 
approach provides a critical first step in combining treatment regimens for diseases that, 
although medically diverse, have interventions with similar operational demands and that 
benefit from shared delivery systems.  
 
For other neglected tropical diseases, including human African trypanosomiasis 
(sleeping sickness), leishmaniasis, Chagas disease, and Buruli ulcer, the main focus is 
on innovative diagnostic tools and treatments. Key control tools will drastically alter 
current control strategies and guarantee ethical, cost-effective and sustainable control, 
aimed at eliminating some of the most difficult neglected tropical diseases.  
In February, WHO and the Foundation for Innovative Diagnostics, with a grant from the 
Bill and Melinda Gates Foundation, announced the start of work to develop and evaluate 
new diagnostic tests for sleeping sickness, a disease that is invariably fatal if not 
detected and treated early in the course of infection. Existing tests are cumbersome and 
difficult to implement in remote, impoverished settings where cases of the disease occur.  
Further support came in October when the pharmaceutical manufacturer, sanofi-aventis, 
announced the donation of medicines for sleeping sickness and direct financial support 
for the control of this disease, leishmaniasis, Chagas disease, and Buruli ulcer. 
 
 
Drug donation is a striking feature of public-private partnerships. In a most welcome 
trend, industry is donating high-quality drugs in great quantities for treatment of 
neglected tropical diseases as shown in Table 1.  
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Table 1. List of donated medicines and contact points for obtaining medicines  
 
Medicine  Donation  Contact point for obtaining 
Albendazole  
Unlimited quantity from 
GlaxoSmithKline for lymphatic 
filariasis only (not for soil-
transmitted helminthiasis) 
For medicines, please contact the WHO 
Representative.  
For information and technical assistance, please 
contact: 
Dr Gautam Biswas  
Department of Neglected Tropical Diseases  
World Health Organization  
CH-1211 Geneva 27, Switzerland  
E-mail: biswasg@who.int  
Tel: +41 22 791 3850 
Eflornithine  
Unlimited quantity by 2012 from 
sanofi-aventis for human 
African trypanosomiasis 
Dr Jean Jannin/Dr Perez Simarro  
Department of Neglected Tropical Diseases  
World Health Organization  
CH-1211 Geneva 27, Switzerland  
E-mail: janninj@who.int/simarrop@who.int  
Tel: + 41 22 791 3779/1345 
Ivermectin  
Directly to countries from Merck 
& Co Inc. for lymphatic filariasis 
and onchocerciasis  
Mectizan® Donation Program 
750 Commerce Drive, Suite 400 
Decatur, GA 30030, USA 
E-mail: mectizan@taskforce.org 
Tel: +1 404 371 1460 
Fax: +1 404 371 1138 
MDT and 
Clofazimine 
Unlimited quantity for  
leprosy and its complications 
from Novartis  
Dr Denis Daumerie  
Department of Neglected Tropical Diseases  
World Health Organization  
CH-1211 Geneva 27, Switzerland  
E-mail: daumeried@who.int 
Tel: +41 22 791 3919  
Mebendazole  
50 million tablets in 2007 from 
Johnson & Johnson for Soil-
transmitted helminths control 
programmes for children 
Nana A.Y. Twum-Danso 
Mebendazole Donation Program & Associate 
Director Mectizan Donation Program 
750 Commerce Drive, Suite 400  
Decatur, GA 30030, USA 
E-mail: ntwumdanso@taskforce.org 
Tel: +1 404 687 5623  
Child Survival Task Force  
Melarsoprol 
Unlimited quantity by 2012 from 
sanofi-aventis for human 
African trypanosomiasis 
Dr Jean Jannin/Dr Perez Simarro  
Department of Neglected Tropical Diseases  
World Health Organization  
CH-1211 Geneva 27, Switzerland  
E-mail: janninj@who.int/simarrop@who.int  
Tel: +41 22 791 3779/1345 
Nifurtimox 
500 000 tablets (120 mg) per 
year by 2012 from Bayer for 
treatment of Chagas disease 
Dr Jean Jannin 
Department of Neglected Tropical Diseases  
World Health Organization  
CH 1211 Geneva 27, Switzerland  
E-mail: janninj@who.int 
Tel: +41 22 791 3779  
Pentamidine  
Unlimited quantity by 2012 from 
sanofi-aventis for human 
African trypanosomiasis 
Dr Jean Jannin/Dr Perez Simarro  
Department of Neglected Tropical Diseases  
World Health Organization  
CH-1211 Geneva 27, Switzerland  
E-mail: janninj@who.int/simarrop@who.int  
Tel: +41 22 791 3779/1345  
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Praziquantel 
200 million tablets 2008-2017 
from Merck KGaA  
for Schistosomiasis 
Dr Dirk Engels 
Department of Neglected Tropical Diseases  
World Health Organization  
CH-1211 Geneva 27, Switzerland  
E-mail:engelsd@who.int 
Suramine 
Unlimited quantity by 2012 from 
Bayer for human African 
trypanosomiasis 
Dr Jean Jannin/Dr Perez Simarro  
Department of Neglected Tropical Diseases  
World Health Organization  
CH-1211 Geneva 27, Switzerland  
E-mail: janninj@who.int/simarrop@who.int  
Tel: +41 22 791 3779/1345  
Triclabendazole 
600 000 tablets 2007-2009 
from Novartis 
for fascioliasis 
Dr Dirk Engels 
Department of Neglected Tropical Diseases  
World Health Organization  
CH-1211 Geneva 27, Switzerland  
E-mail:engelsd@who.int 
  
 
Since the list of NTDs is not exhaustive and has regional and national variations, 
prioritization of diseases is needed and appropriate strategy should be developed. 
Some diseases can be tackled by a multi intervention package on a large scale and 
others require intensified actions in focus areas.  
In October 2006 WHO department of Control of Neglected Tropical Diseases in 
Headquarter arranged a meeting with its Regional focal points to address these issues.  
Each WHO regional office has defined its own prioritized list (see table 2).  
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Table 2. Regional peculiarities and priorities  
 
  
 
REGION  FOCUS DISEASES IN 2006 
AFRO  
Source:  AFRO 
work plan 2006-
2007 [DDC/CPC] 
 
 Buruli ulcer  
 Guinea worm  
 HAT 
 Leishmaniasis  
 Leprosy  
 LF  
 Loa-Loa  
 Onchocerciasis  
 Schistosomiasis  
 STH 
EMRO  
 
Source:  EMRO 
NTD control 
intercountry work 
plan 2006-2007 
 Guinea worm  
 HAT 
 Leishmaniasis  
 Leprosy  
 LF  
 Schistosomiasis and Intestinal Parasitic infections (SIP)  
 ZCL 
 Zoonotic diseases (brucellosis, rabies, hydatidosis) 
PAHO  
Source: Regional 
Strategic 
Framework for 
Prevention and 
Control of ND in 
Neglected 
population in Latin 
America and the 
Caribbean 2006-
2020 
 
 Chagas disease 
 Dengue  
 Echinococcus/ Hydatid  
 Fascioliasis  
 Hookworm infection 
 Leishmaniasis  
 Leprosy 
 Lymphatic filariasis  
 Onchocerciasis  
 Other STH infections  
 Schistosomiasis  
 Taeniasis/ Cysticercosis  
 Trachoma  
SEARO 
Source: SEARO 
work plan 2006-
2007 
[communicable 
disease prevention 
and control] 
 Dengue(dengue haemorrhagic fever  
 Human rabies (70% of global death) and other zoonoses  
 Intestinal parasitoses 
 Japanese encephalaliis  
 Kala Azar (20% of global cases)  
 Leishmaniasis  
 Leprosy (75% of the global cases) 
 LF (50% of global cases) 
 Trachoma and leptospirosis  
 Yaws 
WPRO 
 
WPRO work plan 
2006-2007 
 Control of malaria, other vector borne and parasitic diseases in Cambodia  
 Dengue and DHF control and management  
 Foodborne trematodes  
 Leprosy  
 LF  
 SCH 
 STH  
 Zoonotic diseases 
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REGIONAL OFFICE FOR AFRICA   
 
 
 
 
<To insert AFRO map and list of member countries > 
 
 
 
 
 
 
Africa is one of the most seriously hit continents by neglected tropical diseases.  
People living in the African Region are more exposed to a heavy and wideranging 
burden of disease partly because of this Region’s unique geography and 
climate. The population of the African Region represents about 10% of the world’s 
population, but an estimated 45% or more of its people live below the poverty line, on 
less than US$ 1 a day. Poverty is a major factor determining ill-health, as well as being 
both a cause and an outcome of ill-health. 
 
Control of neglected tropical diseases will invigorate the population in Africa to take 
charge of their own health, promote economic productivity and improve their lives.  
 
Table3: Magnitude of NTDs in WHO African Region  
   
BU GW LESH HAT Leprosy SCH STH LF 
Magnitude 
Number of reported cases Estimated pop at risk 
(million) 
Number of 
reported 
cases 42,852 4628 22,281 14509 44,544 170 400 420 
 
 
BURULI ULCER 
 
With more than 90% of reported new cases of the disease, the WHO African Region is 
the most hit by this NTD.  
Figure 2. Magnitude of Buruli ulcer in AFRO  
The rest of 
the world 
3%
Percentage of 
global disease 
burden 
occurred in 
AFRO 
97%
 
 
26 countries are concerned by Buruli ulcer in the Region; 15 of which are confirmed 
endemic countries and 11 neighbouring ones are considered potentially endemic for 
Buruli ulcer. Since 2000, around 5,000 new cases are reported annually from 8 countries 
and cumulative cases since then are estimated at 50,000.  
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Map 2. BU situation in the WHO African Region in 2006 
                            (Epidemiological extrapolation from country reports in 2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buruli ulcer control programme is combined at Regional level and in some AFRO 
member countries it is combined with the Leprosy Elimination programme, and/or other 
programmes like dracunculiasis, yaws, leishmaniasis and Tuberculosis. Control activities 
are implemented at regional and national levels within the same facilities and with the 
same health staff. 
 
 
Selected country initiatives & success stories  
 
Benin 
Since 1998 Benin set up a specific and vertical BU National control programme.  
The high political commitment enabled the country to mobilize resources through a 
strong partnership with various partners (Association Française Raoul Follereau, 
Association Luxembourgeoise Raoul Follereau, ANESVAD, Tropical Medicine Institute of 
Antwerp, Belgium). Reference hospitals were built in 3 most endemic regions in the 
South of the Country and from those facilities, BU control activities -including IEC with 
community relays, active and passive case finding activities, case management with 
surgery only in the beginning and combined with antibiotic treatment from 2004, 
physiotherapy and social rehabilitation- were decentralized to district level and peripheral 
health centres. Thanks to nationwide survey BU patients who were previously hidden 
from help were found raising the annual number of cases from 395 in 2000 to a 
maximum of 1,045 in 2005. These numbers have been progressively decreasing leading 
the country to combine the BU programme to the Leprosy one at the end of 2006. 
 
 
Nigeria 
Using the Leprosy-Tuberculosis control programme network of staff at State and local 
government area (LGA) levels, Nigeria organised a three month sensitization campaign 
on BU with workshops and IEC sessions in hospitals, medical and paramedical schools. 
This enabled the country to suspect some cases of BU which were later confirmed 
during the assessment visit carried out by WHO with the support of International 
consultant and the Leprosy-Tuberculosis programme staff.  
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Cote d’Ivoire 
Human African trypanosomiasis (HAT), Buruli Ulcer (BU) and Yaws are co-endemic in 
many regions in Côte d’Ivoire (i.e. Daloa,Bouaflé and Aboisso, etc). Studies conducted in 
Côte d’Ivoire have shown that the clinical examination during mass surveys is a feasible 
and suitable strategy for the control of BU and Yaws. There was no extra cost for the 
detection and management/treatment of BU and Yaws. 
 
 
 
DRACUNCULIASIS (GUINEA-WORM DISEASE) 
 
In 1986, he number of persons affected  was estimated at 3.5 millions worldwide.  
Since the World Health Assembly adopted for the first time the Resolution WHA39.21 
calling for Guinea worm disease eradication, the number of dracunculiasis case was 
decreased from 883 640 in 1989 to 4 628 cases in 2006 representing 99.47% reduction  
 
Figure 3. Number of guinea worm cases notified by year in the WHO/ African Region from 1989 
to 2006 
 
In 2006, in the region 8 countries are still endemic: Burkina Faso, Côte d’Ivoire, Ethiopia, 
Ghana, Mali, Niger, Nigeria, and Togo reporting a total of 4 628 cases of guinea worm 
disease. 89% of all cases come from Ghana followed by Mali and Niger 7% and 2% 
respectively.  
 
Figure 4. Distribution of the 4 634 cases of dracunculiasis notified in the WHO African Region, in 
2006 
 
 
 
The new target date for dracunculiasis eradication is December 2009. 
 
Map 3. Certification of Dracunculiasis Eradiation Status as of March 2007  
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Human African trypanosomiasis (Sleeping sickness)  
 
Human African trypanosomiasis threatens 60 millions of people in 36 countries of sub-
Saharan Africa. The prevalence of the disease differs from one country to another as 
well as in different parts of a single country. 
It is difficult to assess the accurate situation in a number of endemic countries because 
of lack of surveillance and diagnostic expertise. 
 
Figure 5 . Magnitude of human African trypanosomiasis in AFRO  
Percentage of 
global 
disease 
burden 
occurred in 
AFRO 
86%
The rest of 
the world 
14%
 
 
In 2005, major outbreaks have been observed in Angola, the Democratic Republic of 
Congo and Sudan. In Central African Republic, Chad, Congo, Côte d’Ivoire, Guinea, 
Malawi, Uganda and United Republic of Tanzania sleeping sickness remains an 
important public health problem. Countries such as Burkina Faso, Cameroon, Equatorial 
Guinea, Gabon, Kenya, Mozambique, Nigeria, Rwanda, Zambia and Zimbabwe are 
reporting fewer than 50 new cases per year. In countries such as Benin, Botswana, 
Burundi, Ethiopia, Gambia, Ghana, Guinea Bissau, Liberia, Mali, Namibia, Niger, 
Senegal, Sierra Leone, Swaziland and Togo transmission seems to have stopped and 
no new cases have been reported for several decades. The known endemicity status is  
shown in Map 4. 
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Map 4. Distribution of human African trypanosomiasis in the WHO African Region, 2006 
 
 
 
Only a small fraction of them are under surveillance with regular examination, have 
access to a health centre that can provide diagnostic facilities, or are protected by vector 
control interventions. Case detection, treatment and prevention in most cases require 
“specialised” human and material resources. 
The control of the disease is expensive and is a major burden to the budget of Ministries 
of health of the endemic countries. Nonetheless, in most endemic countries, HAT 
activities are now included in their national health plans and policy documents are 
available; some of them have appointed a national coordinator or focal point to lead the 
programme and have allocated funds for HAT activities on the national budget. This is 
the case in Angola and in Benin where an annual budget of about USD 1 000 000 and 
USD 100 000 is given respectively by the Governments to strengthen the national 
control programme. 
20 endemic countries out of 21 countries targeted have been supported to implement 
control activities in priority areas. All those countries have reached the performance of 
100% of treatment of cases detected. An accelerated or intensified plan has been 
launched to eliminate HAT.  
In 2006, success in curbing the number of sleeping sickness cases has encouraged a 
number of private partners to sustain the WHO initial effort towards the elimination of the 
disease as a public health problem. The development of partnership for resource 
mobilization at country level was a success story in Guinea Conakry, where the National 
control programme with the support of WHO country office and the HAT inter country 
adviser got a Grant of about USD100, 000 from the Japanese Cooperation for the 
renovation of the HAT reference centre in Dubreka. Sanofi-aventis and IRD (French 
cooperation) are involved in HAT control activities in Guinea. 
 
Clinical trials of combination therapy  
 
WHO is collaborating with TDR, DNDi and national research institutions to promote 
clinical trials of combination therapy in Angola, Congo, DRC and Uganda where the 
disease is refractory to the currently used trypanocids. French Research Institute for 
Development (IRD) in Guinea, Côte d’Ivoire and Burkina Faso, and the Pan African 
Tsetse and Trypanosomiasis Eradication Campaign – PATTEC projects sponsored by 
the African Development Bank in Mali, Burkina Faso, Ethiopia, Ghana, Uganda and 
Kenya. 
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As seen from the figure 6 there is a downward trend in the annual incidence of the 
disease over the past ten years. By 2005, surveillance had been reinforced and the 
number of new cases reported throughout the continent had substantially reduced; 
between 1998 and 2005 the figures for both forms of the disease together fell from 37 
991 to 16378. The estimated number of cases is currently between 50 000 and 70 000.  
 
Figure 6.Time trend of new cases detected in the African Region 1990 – 2004 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Number of people screened by active case-finding surreys, number of new cases of 
HAT reported 1997-2004 
 
 
 
LEISHMANIASIS  
 
Visceral leishmaniasis (VL) or Kala-azar is mainly present in Ethiopia, Kenya and 
Uganda in given foci where the disease can be highly prevalent. More specifically in 
Ethiopia five historical foci are recognized although VL is spreading to non-endemic 
areas. Co-infection of leishmaniasis-HIV reaches up to 35% of the total VL infected 
patients putting some areas of Ethiopia in the top of co-infection world wide.  
 
Selected initiatives  
In May 2005 it was discovered a new foci in Amhara state where 1841 VL cases were 
recorded in 2006. With the help of the Spanish government (AECI), under the leadership 
of the Ministry of Health it was launched a survey to understand the background of this 
epidemic that was completed with specific recommendations for its control. Support was 
provided for case management in the health centers of Addis-Zemen and Metema.  
Active case detection and early diagnosis and treatment have reduced the incidence of 
the disease to a third at the end of 2006 thanks to the activities developed by the 
Regional Health Bureau, MSF-Greece and WHO.  
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Capacity building and guiding  
 
Groundwork for the National Guidelines for the Diagnosis and treatment of leishmaniasis 
was terminated in 2006 for both Ethiopia and Uganda updating in the most advanced 
tools for diagnosis and drugs for treatment.  
 
 
LEPROSY 
 
Elimination of leprosy is defined as the reduction of the prevalence to less than one case 
per 10,000 inhabitants. 42 out of 46 member countries in the Region have achieved the 
leprosy elimination goal at national level. With the average regional prevalence rate of 
0.63 cases per 10,000 inhabitants, the goal of elimination is achieved at regional level in 
the African Region as shown in Table x below. The strategy based on early detection 
and effective treatment of cases with leprosy multi drug therapy (MDT) leads to an 
important reduction of new cases, of people at risk of the disease, and of deformities. 
Four countries yet to reach elimination are: Democratic Republic of Congo, Madagascar, 
Mozambique and United Republic of Tanzania. Leprosy remains a national priority and is 
benefiting from a high political commitment in countries where the goal of elimination is 
not reached. This commitment is translated in to development of plan of action for 
leprosy elimination. These countries are expected to achieve the elimination goal by the 
end of 2007. 
 
Table 4. Indicators in Leprosy Elimination Programme, WHO/AFRO, 2005 
 
End of 2004 
 
End of 2005 
 
Indicators 
Numbers Rates/% Numbers Rates/% 
Prevalence (/10,000) 47,699 0.69 43,587 0.63 
Detection (/100,000) 46,964 6.82 45,179 6.54 
New MB cases  32,042 68% 31,357 69% 
New cases with disability 
grade 2  
5,129 11% 4,562 10% 
New female cases  8,787 19% 10,471 23% 
New child cases  4,928 10% 4,409 10% 
Cumulative relapses  9,247 1% 10,156 1% 
Prevalence / Detection 
ratio  
  1.02   0.96 
Number of countries 
having reached the 
elimination goal  
38 83% 42 91% 
Source: Ministry of Health (MOH) of WHO African States Member 
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In spite of the above-mentioned good results, the infection is still occurring and countries 
in the Region are detecting more than 40,000 new cases every year remaining the 
second most endemic WHO region. There is a need to maintain efforts to sustain 
elimination goal and further reduce leprosy burden in countries.  
The negative image of leprosy among populations and discriminatory attitude 
contributing to the spread of the disease are now largely minimized but still should be 
tackled. While the discrimination against leprosy patients with visible deformity persists, 
the integration of cured people continues to improve. The cure rate is up to 80% in all 
countries because of effective participation of different communities in case 
management activities.   
 
 
LYMPHATIC FILARIASIS 
 
Lymphatic filariasis elimination programme targets 39 endemic countries in the Region 
with an estimated population of at risk of 420 million. To date a population of 139.5 
million has been identified to be at risk in 22 countries where assessment has been 
conducted.  
Mass drug administration of the at risk population using a combination of ivermectin or 
diethylcarbamizine (DEC) and albendazole is on-going in eleven (11) countries covering 
a total population of 38 million. The integration/co-implementation of mass drug 
administration in LF elimination and similar activities in programmes for control of 
onchocerciasis, schistosomiasis and soil-transmitted helminthiasis is being promoted 
and advocacy for partnership around this approach is being intensified. Five countries 
(Guinea, Guinea-Bissau, Malawi, Senegal and Sierra Leone) have developed national 
integrated plans of action for helminthic disease programmes. 
The lymphatic filariasis programmes in Nigeria and Zanzibar have piloted the triple 
therapy with ivermectin, albendazole and praziquantel in communities that have received 
at least five rounds of mass drug administration with combination of ivermectin and 
albendazole and praziquantel in separate administrations. This is part of evidence 
building towards co-implementation of programmes for LF, onchocerciasis, 
schistosomiasis and STH. Available data indicated that 5-6 rounds of MDA with co-
administered drugs were able to bring down the microfilaria prevalence below 1% 
(threshold for interruption of transmission) as shown in Figures 8. 
 
Figure 8. Microfilaria prevalence trend in response to MDA – Example from Zanzibar, Tanzania, 
2006 
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The programmes in Ghana and Burkina Faso reached national scale covering 
approximately 10 million and 13 million people respectively. The other countries that had 
reached national scale in the past are Comoros and Togo. 
A manual providing various approaches and different opportunities for use by countries 
in effecting integrated approach to implementation of NTD programmes is close to 
finalization.  
Disease mapping is still planned in 10 countries in central Africa region. Based on 
epidemiological data the likelihood of transmission having been interrupted over time 
has been reported in three countries (Cape Verde, Mauritius and Seychelles) and 
verification of possible non-endemicity of these counties has been requested.  
The status of lymphatic filariasis elimination programme in the Region is summarized in 
Table 5. 
 
Table 5. Status of PELF in WHO African Region - Mapping and MDA, 2006 
 
Mapping 
Complete & 
MDA started 
(10) 
Mapping 
on-going 
& MDA 
started 
(1) 
Mapping 
complete & MDA 
not started  
(12) 
Mapping on-
going  
(7) 
 
Countries without 
definitive plan for 
mapping  
(10) 
Benin 
Burkina Faso 
Comoros 
Ghana 
Kenya 
Madagascar 
Mali 
Tanzania 
Togo 
Uganda 
 
Nigeria 
  
 
Cape Verde (3) 
Cote D’Ivoire (1) 
Gambia 
Guinea 
Guinea Bissau (1) 
Equatorial Guinea 
Malawi 
Mozambique 
Niger (1) 
Senegal 
Sierra Leone 
Zimbabwe 
Cameroon 2) 
Liberia 
Zambia 
Burundi (4) 
Congo (4) 
Gabon (4) 
Rwanda (4) 
Angola 
Chad 
Central African Republic 
DR Congo 
Eriteria 
Ethiopia 
Mauritius (3) 
Rwanda 
Sao Tome & Principe 
Seychelles (3) 
                             
 
(1) National Plans of action developed 
(2) Re-mapping to be conducted 
(3) Verification of interrupted transmission requested 
(4) At advanced planning stage for mapping 
 
 
Selected country initiatives & success stories  
 
Sierra Leone  
Advocacy to raise funds for implementation of Sierra Leone integrated plan of action for 
helminthic disease programmes has resulted in contributions from Mectizan Donation 
Programme ($115,000) and World Bank lymphatic filariasis Trust Funds ($90,000) to 
support LF mass drug administration co-implemented with onchocerciasis control 
(ivermectin distribution). 
 
Burkina Faso 
The government of Burkina Faso has made an annual allocation of  
USD 400, 000 to the lymphatic filariasis programme and with additional support from 
partners this has enabled the programme in Burkina Faso to reach national scale within 
4 years to cover the entire at risk population of approximately 13 million. 
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Togo 
The LFE activities benefited from the Global Fund for malaria control on the 
understanding that interventions in LF elimination improve outcomes for malaria. 
 
Uganda  
Uganda has extended the activities conducted during Child Health Days Plus to offer 
platform for integrating mass drug administration for lymphatic filariasis elimination, 
onchocerciasis control, and schistosomiasis and soil-transmitted Helminths control. The 
costs of planning, training, and supervision were shared by the interventions conducted 
during this same period (Vit A supplementation, Deworming, LFE, Oral Polio & DPT, and 
measles vaccinations. 
 
SCHISTOSOMIASIS AND SOIL TRANSMITTED HELMINTHS 
 
Schistosomiasis and STH are among the most prevalent public health problems in sub-
Saharan Africa. The morbidity due to a combination of Schistosomiasis and soil-
transmitted helminthes (STH) constitute a heavy public health burden and a clog in the 
wheel of development of affected countries.  Schistosomiasis is endemic in all countries  
except in Lesotho while STH is endemic in all the 46 countries of the Region.  
Seven (7) countries (Burkina Faso, Cameroon Mali, Niger, Tanzania, Uganda and 
Zambia) are implementing national programmes for control of schistosomiasis which 
also includes STH where the two diseases are co-endemic. Activities for control of 
schistosomiasis and/or STH are on-going in a number of other countries. 
Preventive chemotherapy in Schistosomiasis and soil-transmitted Helminths gained 
momentum with countries launching national worm control programmes or linking 
deworming activities with Child Health Day’s or vaccination campaigns. 
The inclusion of deworming in the package of immunizations or Child Health Days has 
greatly increased deworming coverage particularly in children under five years old. For 
example, six countries (Ethiopia, Kenya, Madagascar, Tanzania, Uganda and Zambia) 
have included deworming in either immunization or Child Health Days campaigns which 
are conducted at national or sub-national level. 
 
Selected country initiatives& success stories  
 
Angola 
The Ministry of health with support from WHO, UNICEF and WFP developed a 
comprehensive strategy on School Health Programme. The 1st phase of this plan is a 
de-worming initiative targeting primary school children in the 7 provinces (Cabinda, Uige, 
Zaire, Kwanza Norte, Kwanza Sul, Bengo and Luanda) most affected by parasites 
following a baseline survey in school age children undertaken in 2005.  
In addition, in July/August 2006, a multi-intervention ‘Viva a Vida com Saude’ campaign 
was organized by the Ministry of Health (MINSA) with support from UNICEF, WHO and 
other key partners. The campaign reached 4.1 million children nationwide, reaching 
between 80% and 109% of the target populations for the five interventions included in 
the campaign in which 2.9 million, 97% of the target population was reached. 
 
Burundi, Central Africa Republic and Swaziland 
The three countries combined deworming to national measles campaign reaching 
1,187,269 under five children (113%) out of 1,053,546 in Burundi, 504,026 (91%) out of 
554,314 targeted in CAR, and 126, 326 children  (87,0%) out of 144, 474 targeted in 
Swaziland 
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REGIONAL OFFICE FOR THE AMERICAS   
 
 
 
 
<to be inserted  AMRO map> 
 
 
 
 
 
In Latin America and the Caribbean (LAC) about 25% of the population live on less than 
$2 (US) a day1, over 210 million people (>38%) live below the poverty line, and most 
suffer from a series of neglected diseases 2 (NDs).  
 
The box below shows the percent (%) of global disease burden arising in the Amercias, 
based on Disability-Adjusted Life Years (DALYs). The combined burden of morbidity 
expressed as DALYs and mortality in the American Region is a clear reminder of the 
Unfinished Agenda in Primary Health Care and the need for the Region to move forward 
more rapidly to meet the MDGs by 2015. 
 
Table 6. Percentage of Global Disease Burden arising in the America, based on Disability 
Adjusted Life Years (DALYs)  
 
 
Condition or Disease Percentage (%) 
Chagas disease 99.8 
Trichuriasis 17.7 
Ascariasis 14.6 
Schistosomiasis 10.4 
Leprosy 10.1 
Hookworm Infection 8.2 
Leishmaniasis 2.5 
Onchocerciasis 0.3 
Lymphatic Filariasis 0.2 
Trachoma (b) 0.0 
African Sleeping Sickness 0.0 
(a) Modified from Table 3 in Hotez PJ et al., Clin Infect Dis 2004; 38: 871-8 and Table 1 in Hotez 
PJ et al., Rev Panam Salud Publica 2006;19: 118-23.  
(b) Some cases are reported. 
 
 
There are great opportunities for synergy, cost-savings and sustainability presented by 
integration of ND prevention and control with other diseases, and through inter-sectoral 
                                                   
1
 World Bank.  Latin America & the Caribbean. Poverty Reduction and Growth: Virtuous and Vicious 
Circles, 2006. 
2
 In this report, the term Neglected Disease (ND) will be considered as interchangeable as 
Neglected Tropical Diseases (NTDs), though not all the NTDs in the Region are limited to the 
tropics and subtropical zones (e.g. plague, Chagas disease, fascioliasis, leptospirosis). 
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and inter-programmatic approaches for their prevention, control and elimination.  
Success stories from various parts of the globe, often pioneered by NGOs, have 
encouraged PAHO to plan to test these approaches through proof of concept studies 
based on the design and implementation of small-scale inter-sectoral plans of action.  
These small-scale inter-sectoral plans of action (pilot projects) are now being developed 
in AMRO, the first Region to do so. The concepts of integration and inter-sectoral and 
inter-programmatic action for ND control form the basis for PAHO’s new strategic plan 
framework for the prevention, control and elimination of these diseases in support of 
health equity, well-being and the Millennium Development Goals.   
 
 
LYMPHATIC FILARIASIS  
 
An estimated 8.8 million people are at risk for lymphatic filariasis (LF) infection in the 
American Region. Seven countries in the Americas are listed by WHO as LF-endemic 
with only 4 countries, Brazil, the Dominican Republic, Guyana and Haiti currently 
reporting active transmission. Recent epidemiological and entomological studies indicate 
transmission seems to have been interrupted in Costa Rica, Trinidad & Tobago and 
Suriname.  Interventions which have proven successful to decrease the prevalence of LF 
in the Region include mass drug administration (MDA), selective treatment of individual 
microfilaria carriers and interventions to combat the vector.  
 
 
Selected country Initiatives & success stories  
 
Haiti 
In Haiti an estimated 6 million people are at-risk of infection and approximately 560,000 
persons estimated to be infected. The largest concentration of infection is found in the 
western region of the country (see figure 1). In 2005 over 1.2 million persons were 
treated with DEC and albendazole achieving a coverage of 70% in the targeted areas. In 
2006 MDA did not proceed due to a lack of funds, however, funding has been secured 
for 2007 and nearly 1.5 million people are targeted for treatment this year. Support 
groups to provide care for persons affected by lymphedema are now operating and 
discussions are underway to consider integrating LF and malaria control activities in Haiti, 
as well as a joint LF- Malaria control program for the island of Hispaniola.   
 
 
 
` 
Map 5. LF prevalence and 2005 MDA in Haiti 
MDA 2005 
< 1% 
> 10% 
1-9.9% 
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Dominican Republic  
An estimated 740,000 people are at risk for LF infection in the Dominican Republic and 
an estimated 50,000 are infected. Mapping of the principal areas have been carried out 
(see figure 2), however it needs to be completed in some areas and is scheduled to be 
completed by March 2007. The program to eliminate lymphatic filariasis is based on 
multidisciplinary activities, and is integrated within Primary Health Care in the Barahona 
Region. 
 
 
Map 6. LF distribution in DOR  
 
 
Guyana  
In Guyana 630,000 people are at risk which comprises nearly 90% of the national 
population and 50,000 are estimated to be infected.  In 2003 the program of DEC-
fortified salt was initiated in response to the fact that the at-risk population is widely 
dispersed throughout the country.  Guyana is the only country in the Region using DEC-
fortified salt as the basis of their LF elimination strategy and is working to improve 
coverage and increase production and importation of DEC-fortified salt, which remains a 
major barrier to salt distribution.  
 
Brazil 
In Brazil, active transmission of LF exists in two foci, primarily in the metropolitan area of 
Recife (Pernambuco state), where the entire population of nearly 1,500,000, is 
considered to be at risk.  The second focus for active transmission is in one small area of 
Maceió (Alagoas state), however, it is considered to be in a state of pre-elimination.  
Epidemiological mapping of active foci in Brazil is almost complete with only parts of the 
metro area of Recife remaining. The intervention strategy traditionally followed in Brazil 
has been that of blood surveys and selective treatment of individuals. Since 2003, part of 
the metropolitan area of Recife has adopted an MDA strategy using DEC tablets alone, 
which has expanded from 18,000 initial annual treatments to just over 83,644 annual 
treatments in 2006.  
 
 
ONCHOCERCIASIS 
 
In AMRO the Onchocerciasis Elimination Program for the Americas (OEPA) is 
responsible for its elimination. Partners include PAHO/WHO, Lions Club, Gates 
Foundation, CDC, Carter Center, Merck & Co. Inc., universities and the endemic 
LEGEND 
 
 Negative 
 
 Positive 
 
 Not surveyed  
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countries.  PAHO is a member of the program coordinating committee (PCC) of OEPA 
(along with the national program managers, CDC, Carter Center and others) and is 
involved in the technical review of the OEPA program through participation of its RA for 
parasitology/NTDs in collaboration with the RA for blindness prevention and vision health.   
 
Only six endemic countries remain in the Region (Brazil, Venezuela, Colombia, Ecuador, 
Guatemala and Mexico) with a total of only 13 well-delineated foci. Ivermectin (Mectizan 
donation) is used for mass treatment and distributed twice yearly in active foci to 
eliminate the microfilaria of O. volvolus.  Parasitological, entomological and ocular 
morbidity surveys are conducted periodically to monitor elimination of ocular morbidity, 
parasite transmission and infected vector populations.  Annual meetings (the Inter 
American Conference on Onchocerciasis, IACO) are held to discuss progress towards 
elimination. 
 
All endemic countries far reached the target; more than 85% of ivermectin national 
coverage rates 
 
Currently nearly ½ million people are at risk in 1,950 endemic communities in 13 foci. 
Twice-yearly MDA with ivermectin began in 1995, and up to 11 rounds of twice-yearly 
treatment with ≥ 85% coverage having occurred in five foci. In 2005, over 885,000 
treatments were provided, and by the end of 2006 and for the first time all six countries 
reported achieving ≥ 85% ivermectin national coverage rates, the treatment target rate. 
In 2006 based upon a recommendation from the PCC, Guatemala chose to suspend 
ivermectin treatment in its Santa Rosa focus as transmission appears to have been 
interrupted; epidemiological surveillance will continue for at least 3 years. Transmission 
appears to also have been interrupted in 2006 in Colombia’s single focus.  
 
Table 7. Transmission status in the 13 foci of the Americas Region 2006. Courtesy of OEPA, 
2007. 
Transmission status in the 13 foci of the Americas region
2006
* based upon entomological (PCR) indicator of less than 1 infected fly and 
serology (Ov 16/antigen) negative in children.
11Different transmission statusSouth Chiapas, Mexico
10InterruptedSanta Rosa, Guatemala
Ongoing
Ongoing
Ongoing
Ongoing
Ongoing
Different transmission status
Suspected interrupted
Suspected interrupted
Suspected interrupted
Suspected interrupted
Interrupted
Transmission status*
10Escuintla, Guatemala
10Oaxaca, Mexico
11Lopez de Micay, Colombia
# of rounds>85%Focus
1South, Venezuela
7North-eastern, Venezuela
8Nor-central, Venezuela
10Central Focus, Guatemala
11Amazonas, Brazil
11Esmeraldas, Ecuador
9North Chiapas, Mexico
11Huehuetenango, Guatemala
 
 
As well, ocular morbidity appears to have ended in at least eight foci, showing significant 
advancement towards the regional goal of OEPA to eliminate ocular morbidity by end of 
2007. See Table 2. 
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Table 8. Ocular morbidity status in the 13 foci of the Americas Region 2006. Courtesy of OEPA, 
2007. 
*Extra-sentinel communities
† Based upon MfAC
Ocular morbidity status† in the 13 foci of the Americas region
2006
Ongoing
0% and
3.3%*
2005 
and
2006*
4.2%200121.7%1999North-eastern
Ongoingscheduled2007 8.7%200110.5%1998South
Venezuela
Ongoing2.9%200320.7%1981Central FocusGuatemala
Ongoing2.7%20030.1%199831.2%1995
Amazonas/Ro-
raima
Brazil
Supposedly
eliminated ??
0.2% 
0.0%*
2004 
2006*
0.7%20001.5%1995Chiapas SouthMexico
Eliminated0%20040%200024.7%1991
Esmeraldas / 
Pichincha
Ecuador
Eliminated0%20060%19982.2%1996
Lopez de Micay
(Cauca)
Colombia
Eliminated0%20050%200131%1999North-CentralVenezuela
Eliminated0%2005*N/ASanta Rosa
Eliminated0%2006*6.2%1979Escuintla
Eliminated0%2006*7.2%1981
Huehuetenango
(Cuilco)
Guatemala
Eliminated0%2006*0.6%1995North-Chiapas
Eliminated0%20040.2%20000%1995Oaxaca
Mexico
PrevalenceYearPrevalenceYearPrevalenceYear
Current
status
LastPenultimateBaseline
FocusCountry
 
 
 
LEPROSY 
 
Major progress has been made in leprosy control in the Region of the Americas. A 
number of countries in the Region have instituted leprosy programs that operate in 
accordance with WHO recommendations, have achieved their elimination targets, and 
are in the process of implementing the new WHO Global Leprosy Strategy. Leprosy 
programs in the Region, formerly specialized vertical programs, are becoming 
increasingly integrated and decentralized into basic or primary health-care setups as is 
the case in Paraguay, Colombia, Costa Rica, El Salvador, Mexico and Ecuador.  
Prevalence and new detection rates declined in the Region and elimination status was 
sustained in all countries that have reached elimination (Table 9) 
 
Table 9. Profile of newly detected cases reported by countries* in AMRO 
Country MB Proportion 
(%) 
Female 
Proportion (%) 
Child Proportion 
(%) 
Grade 2 
Disabilities 
Proportion (%) 
Argentina 79.1 40.9 1.3 1.6 
Brazil 50.0 46.3 8.4 4.9 
Bolivia  35.9 41.2 9.6 1.7 
Colombia  68.7 - 3.2 9.7 
Cuba 83.1 44.7 3.8 3.3 
Dominican 
Republic 
 
63.8 
 
50.3 
 
16.1 
 
3.2 
Ecuador  62.9 35.3 0 0 
México 75.4 37.3 2.7 11.7 
Paraguay 77.7 38.5 3.9 7.9 
Venezuela 64.5 33.9 7.2 6.1 
*Countries reporting 100 or more new annual cases 
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The prevalence of leprosy in the Americas Region at the end of 2006 was 32 904 cases 
(0.39 per 10 000) and the number of new cases reported in 2005 was 41 780 (Table 10) 
 
Table 10. AMRO Leprosy indicators, end of 2005. 
Indicators Number of Cases Rate/Proportion 
Prevalence 32 904 0.39/10.000 
Detection  41 780 4.98/100.000 
New case MB 21 845 52.0% 
New cases child 3 402  8.0 % 
New cases disabled  2 107  5.0 % 
 
 
Early detection and integrated programme in primary health service 
 
The countries which have achieved the elimination goal are making efforts to further 
reduce the leprosy burden in accordance with the WHO Global Leprosy Strategy with 
emphasis in early detection and integrated approach in primary health services. Brazil, 
which accounts for the highest burden of leprosy in the Region, has continued to make 
improvements towards the goal of elimination. 
620 health professionals in 11 countries were trained on proper detection, diagnosis, 
treatment and best practices over the last two years. A bi-national case-management 
workshop was held in Haiti and the Dominican Republic to promote capacity building and 
strengthening of basic skills in leprosy control. 
 
 
CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) 
 
In the American Region 15,632,000 persons are estimated to be infected with Chagas 
disease and nearly 30,000,000 live in endemic areas and are considered to be at risk. 
Annually, vector-borne transmission accounts for 41,800 new infections and congenital 
Chagas accounts for 13,550 infections. Chagas seroprevalence in the regional blood 
banks averages 1.28% and table 3 outlines the national seroprevalence for countries in 
the southern cone. Another case of authchnous transmission of T. cruzi in the USA was 
reported in 2006 in addition to imported cases, and nation-wide serological screening of 
blood banks for T. cruzi is being considered. 
 
Table 11: T. cruzi antibody seroprevalence in blood donations by  country in the Southern Cone, 
2006 
Country Prevalence (%) 
Argentina 2.47 
Bolivia 8.0 
Brazil 0.21 
Chile 0.60 
Paraguay 3.2 
Uruguay 0.47 
 
 
Interruption of transmission in more than 80% of the endemic Southern Cone  
 
Trypanosoma cruzi vector transmission has been interrupted in Uruguay (1997), Chile 
(1999) and more recently in Brazil (2006) and large areas of Argentina and Paraguay 
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(see table 4). Transmission in more than 80% of the endemic Southern Cone has been 
interrupted. The National Chagas Control Program has been more rigorously enforced in 
the Andean Sub-region. A surveillance system has been designed and implemented in 
the Amazonian Basin. The Chagas Control Program and the Blood Banks Program 
serologically screen 98% of the blood in endemic countries. While household control of 
Triatoma dimidiata is more advanced in the Region, vector control activities in Bolivia 
have led to a reduction of the peri-domestic vector Triatoma infestans and a reduction in 
pediatric seroprevalence which has been a major achievement for the Region. Control 
efforts have also led to Rhodnius prolixus vector elimination in areas of El Salvador, 
Guatemala and Honduras. Effective control interventions have resulted in a decrease in 
the incidence of acute Chagas cases and a lower prevalence of chronic cardiovascular 
and digestive pathologies leading to a reduction in primary human infections and 
reinfection in exposed populations.  
 
Table 12: Southern Cone Initiative: Interruption of transmission of T. cruzi by Triatoma infestans, 
2006 
Countries Interruption Status in endemic 
areas 
% reduction in 
transmission 
 
Argentina 5 provinces out of 19  26 
Brasil 13 states out of 13 100 
Chile 7 regions out of 7 100 
Paraguay 1 department out of 17  6 
Uruguay 13 departments out of 13  100 
 
 
LEISHMANIASIS 
 
Leishmaniasis is widespread in the Region with cases reported from the south of Texas 
to areas of northern Argentina. In the American Region Colombia, Brasil, Paraguay, 
Venezuela, Panama, Ecuador and Peru have the highest prevalence rates of cutaneous 
leishmaniasis and Brasil has the highest burden of visceral leishmaniasis. Estimating the 
prevalence of leishmaniasis accurately is challenging given that many cases are not 
diagnosed, there are a high number of asymptomatic patients of visceral leishmaniasis 
and the lack of mandatory case reporting. 
 
 
SCHISTOSOMIASIS 
 
Schistosomiasis in Latin America and the Caribbean is caused by Schistosoma mansoni 
only and is endemic in St Lucia, Guadeloupe, Martinique, Suriname, the Dominican 
Republic, Venezuela and Brazil, and perhaps Puerto Rico.  The disease is focal in most 
if not all areas, and morbidity and mortality appear generally low though severe morbidity 
and deaths are still reported in Brazil each year (a fact made visible due to a strong 
surveillance system). National schistosomaisis control programs in Venezuela and 
Dominican Republic appear to be less active in recent years, but Brazil’s programs 
remain active though a Schistosomiasis Control unit (PCE/SVS) in the Ministry of Health 
(MOH) and various states and municipalities which implement passive (and sometimes 
active) case surveillance, and snail surveys. Neuroschistosomiasis cases are reported 
from Minas Gerias state, and this pathology is receiving more attention, particularly in 
the principal endemic states of Minas Gerias, Bahia and Alagoas in Brazil. 
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Selected country Initiatives 
 
St Lucia  
Passive surveillance of schistosomiasis is conducted in St Lucia by the Ministry of Health.  
This involves food handlers and pregnant women who are required to submit stool 
samples for testing. Furthermore, research is currently being conducted by the Spartan 
Health Sciences University School of Medicine on the island. Family members of 
infected individuals are followed up and treatment is provided free of cost. The Ministry 
of Health is also conducting snail control with an objective of eradication around the foci 
where infected individuals are reported.   
 
The situation in St Lucia appears to typify that within the other countries of the 
Caribbean Basin (including Suriname) where schistosomiasis appears to occur in small 
geographic foci at low prevalence. This situation suggests that elimination of the disease 
from theses countries is possible. The government of Suriname has expressed interest 
in the elimination of schistosomiasis from the country and has requested technical 
cooperation from PAHO. 
 
 
SOIL-TRANSMITTED HELMINTHS (STH) 
 
Geohelminths or soil-transmitted helminth infections poses a major public health threat 
and their control is needed to achieve the Millennium Development Goals in the Region. 
In the Americas, children, women, and rural communities have higher prevalence levels 
due to insufficient potable water supplies, inadequate hygiene and excreta disposal 
systems. Prevalence can reach over 70% in some rural communities; however the 
intensity of infection is usually low, with high-intensity infections less common. 
Indigenous populations are also vulnerable to STH infection due to the relative poverty 
that most of these communities experience. An infectious disease review on South-
American indigenous populations 3  found that STH prevalence in many indigenous 
groups was over 50%, and reaching over 70% for Ascaris lumbricoides and Necatur 
americanus. Other published studies record prevalences above 90% in indigenous 
communities in the Region. 
 
 
Multi-disease and inter-programmatic approach  
 
In 2005 an estimated 38% of children living in extreme poverty in the Region were 
covered by deworming programs offered by ministries of health, UN agencies (UNICEF, 
WFP, PAHO) often partnering with NGOs.  
 
PAHO is promoting an intersectoral, multi-disease and inter-programmatic approach for 
the control of geohelminths, combining mass drug administration strategies with health 
education and improvements in water supply and excreta disposal systems, and linking 
other programs such as health schools, healthy municipalities, micronutrient distribution, 
vaccination campaigns, MCH clinics, and with nutrition improvement (improved farming, 
agroforesty) and income-generating activities to combat the poverty that contributes to 
STH infection. Some countries in the Region are already combining these strategies 
within national health plans, such as Haiti and Argentina. Nicaragua and other countries 
                                                   
3
 Hurtado AM et al.  Ann Rev Anthropol,  34: 639-665, October 2005. 
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are taking advantage of national immunization campaigns and national health weeks to 
integrate deworming drug distribution and education. During Vaccination Week in the 
Americas promoted by PAHO/WHO over 17 million women and children in Mexico and 
over 1.1 million in Nicaragua benefited from the distribution of anti-parasitic drugs as well 
vitamin A, folic acid, iron and oral rehydration solutions. At least six countries in the 
Region (Argentina, Haiti, Nicaragua, Honduras, Ecuador and Dominican Republic) have 
established national programs for helminth control often involving NGOs, while others 
(e.g. Brazil, Guyana) carry out passive surveillance and individual diagnosis and 
treatment at the local level. In several of the English-speaking Caribbean nations parents 
deworm their children before each school year begins, though this custom may be on the 
wane. 
 
Two technical workshops to develop plans of action to support scale up of STH control 
by 2010 are scheduled for 2007 in the Region, one of them for English speaking 
Caribbean countries, Haiti and Suriname and the other one for Central America, 
Dominican Republic, Panama and Mexico. These workshops will focus on encouraging 
countries to develop strategic geohelminth control programs based on an 
interprogrammatic, intersectoral and multidisease approach.    
 
 
Selected country initiatives & success stories 
 
Belize  
PAHO and the Ministry of Health, Belize with support from PAHEF conducted a survey 
of soil transmitted helminths among 500 school age children in southern Belize, the 
poorest part of the country.  The study showed that 60% of children were infected with 
STHs with prevalence of Ascaris lumbricoides, hookworm and Trichuris trichiura 
estimated at 24.6%, 22% and 40.2%, respectively.  The study areas which have high 
populations of indigenous Maya, Garifuna, Mestizo and migrants from across Central 
America are characterized by stunting among children combined with high levels of 
poverty and unemployment.  
Following the baseline study, PAHO and the Ministry of Health Belize have drafted a 
multi-disease, inter-programmatic, inter-sectoral project proposal to combat NDs in 
southern Belize. The project will use deworming of school-age children as an entry point 
for the integrated control of soil-transmitted helminths while improving the health of 
women of child-bearing age and pre-school children. The project is also expected to 
develop improved and integrated surveillance of leishmaniasis, leprosy and other skin 
diseases and Chagas disease. Among the expected outcomes of the project is the 
development of sustainable micro-enterprise and agricultural initiatives aimed at 
increasing household income, food security and, indirectly, family health. PAHO has 
identified several partners in the international development community and among local 
and international NGOs who will participate in the non-health related sectors of the 
project. 
 
Haiti  
A strategy for a national school health program based on PAHO’s Health-Promoting 
Schools Regional Initiative (HPSRI) has been recently developed following a workshop 
organized by PAHO, the Ministry of Health and the Ministry of Education to discuss the 
health status of school-age children in Haiti. The draft national school health program 
advocates incorporating STH control and prevention interventions and possible linkage 
with lymphatic filariasis control interventions, within the HPSRI. A World Bank-funded 
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project including deworming is concluding, and it is desired to sustain the deworming 
efforts by incorporation into school health.  A national consultant is to be hired this 
semester to coordinate activities for the elaboration of a strategic plan for the national 
school health program, with field visits and meetings at the departmental level to conduct 
a situation analysis and a second workshop to finalize the strategic plan. 
 
 
CYSTICERCOSIS AND TAENIASIS 
 
Cysticercosis in LAC is widespread, reported from Mexico and several countries in 
Central and South America including Guatemala, Honduras, Belize, Nicaragua, Ecuador, 
Peru, Bolivia, Colombia, Venezuela and Brazil. 
There is no regional or sub-regional network dedicated to the prevention and control of 
this disease, nor is the condition usually reportable.  Therefore there is no general 
political will towards its prevention and control among the countries, particularly on the 
human health side.  This is also no agreed standard for the diagnosis of cysticercosis 
and taeniasis in humans or porcines and prevalence estimates may not be directly 
comparable among countries.    
The prevalence of neurocysticercosis, based on autopsy, imaging and immunological 
methods, range vary widely from Colombia (1.82%) to Peru (7.1 to 26.9%), whereas in 
Ecuador prevalence was estimated at 8.6-10% using immunoblots and 14.4% based on 
CT scan.  Prevalence of human taeniasis appears to be generally low across the Region, 
but surveys are needed.  Using stool examination, coproantigen detection, self detection 
and post treatment recovery following estimates were obtained: Peru (0.8-2.8%), 
Ecuador (0.66-1.60%), Mexico (0.5-1.2%), Honduras (0.77%).  In contrast, prevalence in 
Venezuela was reported to be 11%.  These studies reflect the scope of the problem 
within particular foci but the problem remains on a national level in Bolivia, Nicaragua 
and Guatemala.  Important risk factors for cysticercosis in the Region appear to be the 
presence of a taeniasis case in the household and the free range rearing of pigs which 
allows them to consume human excreta. 
 
 
FASCIOLIASIS, PARAGONIMIASIS AND CYSTIC ECHINOCOCCOSIS 
 
Human fascioliasis is widespread but occurs at low prevalence in several countries in 
South America from Argentina and Brazil to Ecuador, Mexico, and Guadeloupe and 
Puerto Rico in the Caribbean.  However, there are areas where it is a significant cause 
of disease among school-age children and young adults - in Bolivia significant 
prevalence rates for human infection by Fasciola hepatica were reported from 24 
localities (0-68%) in the Northern Bolivian Altiplano.  The highest prevalence was in 
persons less than 20 years old and there was no gender difference. There was a higher 
intensity among girls of school age and a decrease in mean egg counts was seen with 
an increase of age.   Infection rates have been reported to exceed 70% among local 
workers in Bolivia. 
In Peru prevalence and intensity vary widely from but may be as high as 34.2% in the 
some regions of the Peruvian Altiplano.  Several risk factors for transmission have been 
identified including residence in a livestock rearing area, consumption of alfalfa juice and 
contaminated drinking water. 
Paragonimiasis in the Americas occurs among rural populations, including several 
indigenous populations, in several countries throughout the Region (e.g. Peru, Ecuador, 
Colombia, and Venezuela), but prevalence appears low though morbidity is unknown. 
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Morbidity in humans and livestock from Hydatid disease continues in the Region; a 
recent study of cystic echinococcosis noted an estimated total of 52,693 DALYS lost, 
while economic losses total more that $120 million per year in the Americas4. 
 
 
PARASITIC SKIN DISEASES  
 
Data on parasitic skin diseases in AMRO is sparse.  However, they have been shown to 
be a serious cause of morbidity in poor populations including indigenous communities in 
the Region. Prevalence of head lice can has been reported to be as high as 43% among 
resource poor populations, while scabies may affect almost 10% of school age children 
in these communities and has been reported at much higher prevalence in some 
indigenous communities. Tungiasis is present and crippling in some indigenous and 
fisher communities; while cutaneous larva migrans is present in some poor communities 
and adversely affects beach tourism in some places in the Caribbean. Recent sentinel 
surveillance data on travelers to the developing world found cutaneous larva migrans as 
the most common dermatological disorder among patients presenting after travel to the 
Caribbean, while leishmaniasis was found mostly in patients who had traveled to South 
America, and myiasis was reported most frequently among patients who had traveled to 
Central or South America.5 Numerous cases of human myiasis associated with the New 
World screw-worm fly (a livestock pest) are reported in Jamaica, Colombia and Brazil 
and other countries. 
 
Selected country Initiatives  
 
Haiti and Ecuador  
Two project proposals are under development by PAHO working with partners to 
address parasitic skin diseases (excluding leprosy and leishmaniasis) in Ecuador and 
Haiti. In Ecuador a project that integrates deworming and skin disease treatment into 
current disease-control programs for malaria, TB, and onchocerciasis among the 
indigenous population in the province of Esmeraldas is under revision. In Haiti the 
control of infectious skin diseases (in particular scabies, cutaneous anthrax 6  and 
superficial mycoses) will be part of a integrated, inter-programmatic and inter-sectoral 
(improved water supply, agroforesty, small animal production and health) small-scale 
plan of action for ND control in the upland area of the Artibonite Valley, in partnership 
with Hopital Albert Schweitzer and the MOH. 
 
 
DENGUE  
 
During the period 2001-2005 over 30 countries in the Region reported 2,879,926 dengue 
and hemorrhagic dengue cases with a total of 789 deaths. Each of the four subtypes 
(DEN 1, DEN 2, DEN 3, DEN 4) circulated in the region. The southern cone countries 
                                                   
4
 Budke CM et al. 2005. Global economic impact of cystic echinococcosis. Emerg Infect Dis 12(2): 296-
303. 
5
 Freedman DO et al. 2006. Spectrum of disease and relation to place of exposure among ill returned 
travelers.  N Engl J Med 2006, 354:119-130. 
6
 Veit HP  et al.  The relationship of Haitian small farm management to goat and cattle diseases. 
Rev Elev Med Vet Pays Trop. 1993;46(1-2):39-45.  Veit HP et al. A survey of goat and cattle diseases in 
the Artibonite Valley, Haiti, West Indies.  Rev Elev Med Vet Pays Trop. 1993;46(1-2):27-38.  Smego RA 
Jr. et al. Cutaneous manifestations of anthrax in rural Haiti.  Clin Infect Dis. 1998 Jan;26(1):97-102. 
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reported 64,6% of the total cases in the region with 1,859,259 dengue fever cases,  
4,509 dengue hemorrhagic fever cases and  258 deaths. The Andean sub region 
reported 580,589 cases of dengue fever and dengue hemorrhagic fever (21,1% of the 
regional total) and 221 deaths. Central America reported 10,6% of the total, with  
289,929 cases of dengue fever and dengue hemorrhagic fever,  and 133 deaths. The 
Caribbean sub region reported 2.6% of the regional total with 76,222 dengue fever and 
dengue hemorrhagic fever cases. Chile and Uruguay are the only countries in the 
Region with no reported transmission. Haiti, despite having no apparent dengue 
hemorrhagic fever, has hyperendemic virus transmission, though reported data on the 
number of dengue cases is lacking. 
 
The main control strategy in the Region is the Integrated Management Strategy for 
Dengue/DHF at the sub regional and national levels. Its main objective is to promote the 
integration of six components: social communication, entomology, epidemiology, 
laboratory, patient care and environmental management. The strategy includes the 
COMBI method to promote behavioural changes in the individual and the community for 
dengue prevention and control. A sub regional level working group (EGI) has been 
established in Central America and another one is planned for countries in MERCOSUR. 
National level EGIs are being developed in several countries: Brazil, Colombia, Costa 
Rica, El Salvador, Guatemala, Honduras, Nicaragua, Panamá, Paraguay, Dominican 
Republic and Venezuela. 
 
At the regional level there are two main initiatives for dengue, Integrated Vector 
Management (IVM) and DENGUE-NET. IVM seeks to apply cost-effective strategies to 
control dengue as well as other prevalent vector borne diseases in the region. DENGUE-
NET is a web-based surveillance system for dengue case reporting. 
 
 
BLINDING TRACHOMA 
 
Trachoma is apparently endemic in only a few countries in LAC, among them Brazil, 
Mexico and Guatemala and perhaps Bolivia and Peru; in the recent past it was reported 
from Haiti and Jamaica. Brazil and Mexico have active trachoma prevention and 
control/elimination programs, and are implementing the SAFE strategy.  In an earlier 
study (2002) in NE Brazil, prevalence of active trachoma disease ranged from 5% to 
42%.  As a part of a national survey which will be completed soon, Brazilian health 
authorities found about 10,000 cases among 250,000 people examined in 2004. Brazil 
screens for active disease in schoolchildren and maps the distribution and prevalence of 
infection.  In Chiapas, Mexico, a recent water and sanitation project by the Pan American 
Center for Sanitary Engineering and Environmental Sciences, part of PAHO, was 
implemented to reduce the prevalence of trachoma. As well the NGO Helen Keller 
International works in Mexico to combat trachoma. The PAHO trachoma elimination 
program promotes the SAFE strategy.  It is coordinated by the RA for Blindness 
Prevention and Vision Health, located in another PAHO technical area and unit. 
 
 
INTEGRATED VECTOR MANAGEMENT 
 
Over the last two years the Region has developed a draft regional strategic plan for 
integrated vector management (IVM), and will be adapting it to reflect the forthcoming 
WHO Global Plan to Combat NTDs 2008-2015 and its IVM components.  
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During 2006 and early 2007 technical cooperation (TC) has been provided, among other 
countries, to Bahamas and Jamaica to address malaria vectors involved in malaria 
outbreaks arising from imported malaria cases. In addition to on-going TC, during 2007 
several IVM initiatives and activities are planned to unfold. 
 A PAHO-developed pesticide applicators certification program is approaching 
roll-out. Course materials and a course outline are prepared. Several countries in 
the English-speaking Caribbean and Brazil are interested in establishing the 
program; in the case of Brazil it may involve the agricultural sector and the health 
sector together. 
 A situation analyses to determine the technical capacity in medical entomology 
and IVM are needed, to address the apparent dearth of expertise in many 
Ministries currently. A preliminary evaluation was conducted in Guyana recently; 
other countries will need evaluation to determine capacity and needs.  
Additionally a bi-national meeting Guyana-Suriname to address LF surveillance 
and Culex vector control through WS&S and IVM is anticipated for the second 
half of 2007. 
 Technical cooperation to countries to advise on insecticide susceptibility testing is 
needed, especially to countries experiencing dengue epidemics or malaria 
outbreaks and MOH are considering switching insecticides to control them. 
 The draft regional strategic plan for IVM needs articulation with and input from 
other CD strategic plans particularly those for malaria, dengue, Chagas disease 
and neglected diseases, before it is finalized. A meeting of the respective RAs 
and other key persons is needed this year to receive their input into the IVM 
strategic plan. This will also be the opportunity to begin the development of 3 pilot 
projects inserting IVM into on-going programs or new projects for control or 
elimination of vector born diseases (VBDs) such as malaria, LF and Chagas 
disease. 
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COUNTRY FOCUS: HONDURAS 
 
Honduras is a new model of an integrated neglected tropical diseases control 
programme that includes health promotion and a search for and involvement of new 
partners. The national programmes are based on comprehensive actions, involving 
different actors in both the health sector and other sectors. 
 
COUNTRY INFORMATION 
 
Total population: 7 362 000 inhabitants 
Population living in rural areas: 53% 
Population below poverty line: 20.7% 
Enrollment rate (primary school): 79% 
Gross domestic product per capita (GDP): 2 900 
Public spending in health per capita: US$ 41 
 
MAGNITUDE OF NTDS 
 
STH  Infection   Number of inhabitants at risk: 7 250 000 
Prevalence: 33% for A. lumbricoides, 39% for Trichuris trichiura, 
4.9% for hookworms 
 
Chagas disease  Number of inhabitants at risk: at least 300 000  
Prevalence: 4.6% in children under 15 in areas endemic; 1.4% in 
adult population of blood donors, proportion of congenital disease 
in endemic areas approximately 10-33% 
 
Dengue  Number of inhabitants at risk: 6 575 000 
 Incidence: 128.3 per 100 thousand inhabitants (2006) 
 
PROGRAMMES AND INITIATIVES 
 
Soil-Transmitted Helminthiasis  
 
In 2003 a national survey in school-age children was conducted to form a quantitative 
basis for the establishment of a national control program of soil-transmitted helminthiasis. 
Involvement of external donors (NGOs, multi-lateral and bi-lateral aid agencies) and 
technical cooperation agencies (PAHO/WHO, World Food Program WFP) is a key 
element of the control strategy.  Currently pilot projects involving articulation with NGOs 
distributing vitamin A and maternal and child health programs are under way.  
Honduras continues to extend deworming coverage where feasible by integration with 
other disease prevention and control programs, especially the programs for Chagas 
disease and leishmaniasis control, maternal and child health and child immunization 
programmes, and the food security programs.  
 
Chagas disease 
 
Honduras has been one of the founding countries of the Central American Initiative for 
Control of Chagas disease (IPCA) within the framework of the Special Meeting of the 
Health Sector of Central America (RESSCA), in 1997.  
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The Honduras National Program for Chagas disease in coordination with PAHO/WHO, 
JICA, CIDA, and other agencies has been increasing the coverage and quality of its 
actions:  
• Since 1991, a 100% coverage of screening of blood for T. cruzi infection has been 
achieved in all the blood banks thanks to a compulsory blood screening law 
established in 1985.  
• Blood samples were taken in 32,740 schoolchildren of 1,146 primary schools in 62 
municipalities over the period of 2005-2006.  
• In 2005, 28 521 houses were treated with insecticides in 1,092 localities in 51 
municipalities. 
• Endemic Rhodnius prolixus vector has been eliminated from 146 localities in 44 
Municipalities.  
• Triatoma dimidiata vector has been restricted to only 17% of the intradomiciliary 
areas and to 0.5% of the peridomiciliary areas where this species is recorded.  
 
The Strategic Plan of Chagas disease 2003-2007 has set Honduras on the path for 
achieving the goal of elimination of the vector-borne and transfusion transmission of T. 
cruzi by year 2010.  
 
Dengue 
 
Dengue has epidemiological, social, and economic impact and constitutes a growing 
threat for Honduras. From year 2001 up to 2006 a total of 105,155 dengue cases were 
recorded. This included 6,528 cases of dengue hemorrhagic fever and 36 deaths.  
In September 2004 a national strategy for dengue (EGI-Dengue Honduras) was 
launched with the creation of a dengue working group. Environmental sanitation is now 
being done at Municipal Governments level, and multidisciplinary intersectoral 
commissions have been created, such as the Commission of Environment, Regulation,  
Education, Promotion and  Surveillance. In each of the departments the national strategy 
has been adapted to its local realities and to the available resources.  
Additionally a sub-regional Workshop on Communication for behavioral impact (COMBI) 
for dengue control was held in 2003 where Honduras prepared a National COMBI Plan 
and trained a national multidisciplinary group. This plan has been only partially executed 
due to lack of full financing.  
 
The country’s poverty conditions, the migration of population from rural to urban areas, 
unstructured urban growth, inadequate housing, deficient water supply, low school 
attendence, low awareness of the diseases and of their transmission vectors are 
determinants that increase the risk of infections by neglected tropical diseases. These 
are the factors that need to be modified by an inter-sectorial and inter-institutional 
approach with rational utilization of international technical cooperation.   
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 REGIONAL OFFICE FOR THE EASTERN MEDITERRANEAN   
 
 
 
 
<To be inserted EMRO map and list of member states>  
 
 
 
 
 
DRACUNCULIASIS  
 
18 out of 21 member states of the WHO Eastern Mediterranean have been certified by 
the International Commission for the Certification of Dracunculiasis Eradication (ICCDE) 
as being free of dracunculiasis transmission. Four countries are still not certified. They 
are Afghanistan, Djibouti, Somalia and Sudan.  
 
 
Selected country initiative  
 
Sudan  
Sudan is still endemic country with 81% of world-wide reported dracunculiasis cases. 
The northern states have interrupted disease transmission in 2003.Transmission occurs 
only in the south of the country. In the northern states of Sudan, only imported cases are 
registered. Sudan reported significantly higher number of cases of dracunculiasis in 
2006 compared to 2005 as a result of improved accessibility to areas of southern Sudan, 
establishment of infrastructure of the guinea worm eradication programme in newly 
discovered endemic areas and provision of logistical support to activate surveillance and 
monthly reporting of cases. 
Implementation of the eradication interventions, including the case containment strategy 
and provision of safe sources of drinking water, were improved in main endemic areas in 
Southern Sudan. The Regional Office in cooperation with the Carter Center was 
supporting the national Guinea Worm Eradication Programme to strengthen its 
surveillance and interventions activities. Particularly, WHO supported the organization of  
refresher training courses for village volunteers in formerly endemic areas in 6 northern 
states. Support was provided for organization of special surveys in selected previously 
inaccessible areas in the southern states in Sudan. Surveillance activities included 
provision of advocacy materials to the communities, collection of data about availability 
of safe drinking water and carrying out rumors investigation. All rumors of dracunculiasis 
cases have been investigated and population of villages with identified dracunculiasis 
cases were covered with distribution of water filters for individual protection against 
dracunculiasis. In southern Sudan, surveillance and supervisory structures were carried 
out in 8 out of 10 states.  
 
LEISHMANIASIS  
 
EMRO countries concentrate a high prevalence of cutaneous leishmaniasis (CL) world 
wide, such as Afghanistan, Iran, Pakistan, Saudi Arabia, Sudan and Syria. Although CL 
is not a killing disease, it causes a high stigma mainly in women and implies a high 
disease burden in these areas (approximately 12% of the total 2.3 billion DALYs caused 
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by leishmaniasis). A major CL epidemic is occurring in Afghanistan which is spreading 
the disease to neighboring countries like Pakistan (Singh and Balochistan province). On 
the other hand, visceral leishmaniasis (VL) is also prevalent in some EMRO countries, 
mainly Sudan - the second largest foci in the world.  
 
Selected initiatives  
 
In Sudan, the highest VL endemic states are Gedaref and Upper Nile, in both of them 
WHO has contributed with a coherent support in regards case management and 
epidemiological surveillance, after a donation of the Spanish government (AECI).  
The epidemic of CL in Kabul, Afghanistan, has been also a matter of special interest for 
WHO where 11 300 patients got treatment during 2006 thanks to a donation of the 
Belgium government. A KAP study was also a key activity to better understand the 
transmission and impact of CL in Kabul.  
 
Capacity building and guiding  
 
Morocco is endemic of CL and VL. In particular CL has been spreading due to 
"Leishmania tropica" in the hills close to the Atlas, with more than 1000 cases a year for 
several consecutive years. In order to contain the spread of the disease, 45 health 
workers were trained either in microscopy skills or program management.  
Interactive maps reviewing 25 years of scientific literature in regards human 
leishmaniasis, sandfly vectors and reservoir hosts have been finished for all EMRO 
countries bordering the Mediterranean sea.  
 
 
LEPROSY  
 
Tremendous progress in reducing the burden of leprosy through the widespread 
implementation of multidrug therapy (MDT) was achieved in the endemic Member States 
of the Eastern Mediterranean Region. The number of registered cases in the Region has 
significantly decreased from 74,892 cases in 1985 to 23,219 cases in 1995 and to 4,024 
cases by the end of 2005. Accordingly, the prevalence of leprosy per 10,000 population 
at the Regional level decreased from 1.58 in 1985 to 0.12 in 2005.  
 
All member states reached the target of leprosy elimination as a public health problem at 
the country level.  
The regional target to eliminate leprosy as a public health problem by 2005 at the sub-
national level was achieved at provincial (state, governorate) levels and at the district 
level in the majority of endemic countries. The number of annually registered new 
leprosy cases decreased at the regional level from 5,565 cases in 2000 to 3,836 in 2005. 
Accordingly, the detection rate per 100,000 population decreased from 1.21 in 2000 to 
0.8 in 2005. 
 
Improved access to leprosy diagnosis and MDT drugs free of charge remain the 
cornerstone of the leprosy elimination strategy. The adherence to treatment of leprosy 
patients was significantly improved after introduction of MDT blister packs for adult and 
children patients with MB and PB leprosy. During 2000-2005, WHO supplied Member 
States on their request with free of charge 535,782 MB and 79,098PB adult blister packs 
and 42,440 MB and 22,960 PB child blister packs. In addition, Novartis has also donated 
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through WHO 14,000 tablets of 50 mg and 73,000 tablets of 100 mg clofazimine for the 
treatment of patients with severe leprosy reactions. 
 
Integration of leprosy control programme into primary health system  
 
The integration of leprosy control services within general health-care systems and the 
phasing out of vertical programmes are being carried out by national programmes based 
on country-specific local situations. WHO focused on strengthening national capacity on 
diagnosis and treatment of leprosy by supporting the organization of training courses for 
PHC staff, dermatologists, laboratory technicians, social workers and staff of non-
governmental organizations. Support was provided for strengthening community 
awareness on leprosy through printing and distribution of health education materials, 
organization of meetings with community leaders and press media. 
 
Capacity building in Egypt, Pakistan and Sudan  
 
The Regional Office continued to assist the national programmes in Egypt, Pakistan and 
Sudan with strengthening national capacity on diagnosis and treatment of leprosy by 
supporting the organization of training courses for PHC staff, dermatologists, laboratory 
technicians, social workers and staff of the non-governmental organizations. Regular 
training of PHC staff and dermatologists in diagnosis of leprosy facilitated early diagnosis 
of cases and reference of them for MDT treatment to leprosy clinics. In addition, training 
was organized to social workers in provision of counseling and socio-economic 
rehabilitation to leprosy cases. 
 
A regional meeting of national coordinators and partners on integrated leprosy control 
was organized by the Regional Office in June 2006 in Alexandria, Egypt to review 
progress in sustaining leprosy control activities, discuss approaches for integrated 
control within the existing health systems and discuss collaborative activities with 
partners. The meeting recognized the achievements made by individual national 
programmes in sustaining leprosy control services and emphasized the importance of 
continuing control activities in an integrated manner between all partners. 
The national programmes continued efforts to sustain already made achievements in 
leprosy control and to maintain quality and coverage of cervices at affordable cost to the 
programme and the community. All leprosy clinics in Egypt at governorate level have 
been integrated with dermatology services.  
 
National seminar in Morocco was held in May 2006 to discuss restructuring of the 
leprosy services into National Skin Disease Programme which will include control of 
other skin diseases.  
 
Pakistan adopted strategies to maintain sustainability of the leprosy control programme 
by net-working with the national blindness and tuberculosis control programmes and 
integrated leprosy into basic dermatology in special action projects (skin camps) to cover 
all hyper-endemic areas.  
 
 
LYMPHATIC FILARIASIS  
 
WHO recommended strategy of mass drug administration (MDA) to bring down 
transmission of lymphatic filariasis was successfully applied in Egypt and Yemen with a 
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significant reduction in public health significance of the disease. Egypt was able to 
achieve elimination of LF in the majority of endemic areas with 5 rounds of annual 
application of combination of diethylcarbamazine (DEC) and albendazole tablets. The 
effect of MDA was measured by the most specific and sensitive parasitological and 
immunological methods. During 2006 MDA continued in some areas with less than 5 
rounds and in areas where the criteria for stopping MDA has not been met yet. Yemen 
completed the fifth round of MDA using the ivermectin plus albendazole combination in 
all endemic areas. Mapping of lymphatic filariasis endemic areas in Sudan is in progress. 
 
 
SCHISTOSOMIASIS AND SOIL TRANSMITTED HELMINTHES 
 
 Schistosome and Soil-transmitted helminths (STH) infest large populations in certain 
regions of the EMR with the most intense infections in children and the poor.  In addition 
to causing much suffering and death, these infections contribute to perpetuating poverty 
through impaired cognitive development and growth of children, and decreased work 
capacity and productivity in adults. Control of these diseases is however possible using a   
simple Strategy  based on repeated, regular treatment with ( cheap and safe) single-
dose anthelminthics of the highest risk group (school age children)  that can be reached 
through the primary school health system or other ongoing health or education 
programmes. This is how many countries of the EMR totally interrupted transmission or 
reached now a low endemic-low morbidity status. Actually, Schistosome and STH 
infections remain a major public health problem only in Sudan and Yemen.    
Two major different challenges are faced actually: 
In the low endemic countries, the major difficulty is how  to sustain the programmes  by 
the maintenance of the same level of human resources and funding for the coming 
years , in order to avoid a disastrous and  costly recrudescence,  when  schistosomiasis  
does not represent anymore a public health problem in these countries ( Egypt, Saudi 
Arabia Syria, ,Morocco, Libya, Oman. How to avoid repetition of situations such as  in 
Gezira State (Sudan), where the Blue Nile project resulted in an elimination of 
schistosomiasis in the end of the 80s and where the actual endemicity is among the 
highest in the world. 
In the still high endemic countries (Sudan and Yemen) the challenge is to support the 
national control programmes of to adopt and properly implement the WHO strategy, 
ideally with integration into ongoing health and education initiatives and with the 
participation of other partners such as WFP and UNICEF, or others, as currently done in 
Afghanistan. In fact, the real difficulty is to ensure a regular sustainable system of drug 
delivery to the target population in these countries. 
 
Action taken and results achieved: 
 
Successful countrywide deworming campaign was continued in 2006 in Afghanistan, in 
28 targeted provinces out of 34 thanks to sustained partnership with UNICEF and WFP   
and mebendazole drug donations. 
In Egypt, The School Health Programme was expanded to cover eleven (Egypt is 
divided in 26 governorates) more Governorates of the country, (Dakahalia, Kalubyia, 
Sharkia, Kafr El Sheik, Gharbia, Monufeya, Ismailia, Damiatta, Fayum, Beni Suef and 
Rural Alexandria), in addition to Behera (the pilot phase area). This represent a 
coverage of almost half (30 millions) of the total population of the country and about two 
thirds of those living in rural areas.  
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Monitoring surveys following Praziquantel distribution confirmed further lowering of   S. 
mansoni overall prevalence  in 12 endemic districts to 1.5% and the persistence  at very 
low level 0.2%, of S. heamatobium, in only one district of the Governorate of Beni Suef ).  
Prevalence and intensity of infection with Soil-Transmitted Helminths (STH) has also 
been reduced in the six endemic districts, with three of these districts not reporting 
anymore moderate/high intensity of infection. 
In regard to human fascioliasis endemic foci have been identified in rural Alexandria, 
Behera, Gharbia and Kalubyia and control activities directed toward specific areas are 
ongoing as planned, using triclabendazole provided by WHO. 
 
In Saudi Arabia, evidence from surveys and long period surveillance confirmed in 2006 
that  local transmission of schistosomiasis ceased in some regions ( Tabuk, Hail, Al Jouf,  
Riyadh , Najran ) with no reports of locally contracted schistosomiasis.  In other regions 
(  Maka Al Mukaramah, Al Medina AL- Manawarah, Al Taif, and Jeddah) only not locally 
contracted cases were reported. Jazan region didn’t register cases in 2006 but remains 
at high risk because of the movement of people to and from Yemen and the common 
wadis that introduce snails into Jazan during floods. All these factors threatens the 
elimination of schistosomiasis from that region where snail control is now the highest 
priority and requires to be sustained until effective control measures are implemented 
along the border from Yemen side.  
The re-emergence of new cases in Albaha is probably due to the demobilization that 
occurred following the achievement of the elimination targets that were reached in 2005 
in this area and emphasizes the need to sustain activities for a long period following 
morbidity and prevalence control, by an intensified program to detect and control the few 
remaining cases and potential remaining transmission spots . 
  
Sudan was supported to initiate the implementation of mass treatment in Gezira. In 2006, 
the programme was implemented in 2 very high endemic localities (48% prevalence) and 
was successful in one locality where almost 300 000 tablets of praziquantel were 
distributed, ensuring the coverage of 11 983 persons, representing 60% of the targeted 
population. Less coverage (30%) in another locality was explained by insufficient 
preparedness of population to accept the drug and weak health education to counter a 
rumor that the drug has severe side effects. 
 
In the southern part of Sudan, insecurity problems affected the implementation of the 
schistosomiasis programme. However, WHO staff in the field successfully integrated 
deworming activities and Vitamin A distribution with other programmes especially within 
the polio program (that have been re-located in Juba). 2 million tablets of albendazole 
provided by WHO, were distributed during national immunization days (NIDs). 
  
In 2006, in Yemen, WHO supported the assessment of the programme and revealed 
several weaknesses, such as the use of costly surveys followed by treatment of 
individual detected cases instead of expanding community based mass treatment, in 
addition to the use of a quality uncontrolled praziquantel. Moreover, at periphery level 
there is a tendency to set up new independent programmes instead of using already 
existing systems in schools or mobilising partnerships with partners working on the same 
targets. This probably explain why, despite many commendable efforts in this country 
and investments (local and from WHO) there is not yet any visible impact on morbidity or 
prevalence.  
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TRYPANOSOMIASIS OR SLEEPING SICKNESS : 
 
Sudan was the 3rd most endemic country of human African trypanosomiasis. HAT 
requires high skilled personnel to be diagnosed ( early stages are pauci-symptomatic) 
and require invasive techniques (lumbar punction) to be staged (2). Only highly toxic 
injectable drugs are available for its treatment and require long treatment courses in 
available hospitals. The existence of more than 20% of resistance with Melarsoprol in 
some areas in South Sudan constitutes an additional difficulty. The alternative being to 
use eflornithine which requires 56 perfusions in 2 weeks for each patient. 
 
The initiative launched  by WHO, in 2002,  in partnrership with Aventis (now sanofi-
aventis) and NGOs led  the control the disease with  very low prevalence (less than 1%) 
achieved  in almost all foci . This was realized thanks to the presence of permanent 
WHO staff in the field ensuring the free distribution of all necessary diagnostic tools and 
drugs, training, rehabilitation of treatment centres and laboratories, coordinating between 
implementing partners and  tackling cross-boarder issues. However, the situation was 
fragile and during the last 2 years, the principal challenge was how to sustain a quality 
comprehensive programme, when some important specialised NGO partners started to 
pull out, and how to replace or ensure the transition to nationals  to build up a sustained 
control system. The other challenge was how to generalize/upgrade all treatment 
facilities for the newer 2 weeks treatment (DFMO) regimens, as still few facilities 
continue to use the very old 3 week more toxic  regimen of Melarsoprol. 
 Another important challenge will remain that is the need to ensure , in southern Sudan, 
laboratory capacities to ensure continuous adequate follow up of Trypanososma drug 
resistance . 
 
Action taken and results achieved: 
 
The WHO team succeeded to sustain the situation under control in all foci of (Juba ,Kajo-Kegi. 
Yei County, Tambura and Ezo County) except in Maridi and Mundri, two counties of West 
Equatoria State where the situation deteriorated following the departure of  MSF-France . The 
stage 2 treatment is no longer available locally and patients need to travel far to seek for 
treatment. In this transition period and to ensure sustainability of control , The WHO team 
continued to focus on training , rehabilitation and coordination including across boarders. 
As for the last four years Southern Sudan has acquired a large experience in the use of 
eflornithine (DFMO), as first line treatment for late stage (stage 2) of sleeping sickness, 
with a lower fatality rate compared to the classical old drug (melarsoprol), it started  
sharing this  expertise in an 12 days International Training Course (in Yei, Central 
Equatoria State) on the use of DFMO as first line with participants from Angola, 
Democratic Republic of Congo, Republic of Congo and Ivory Coast (10 participants in 
total). The aim was to  help these endemic countries to adopt eflornithine in their 
treatment protocols.  
Another major event organized and sponsored by WHO in 2006, was the Fourth 
Sleeping Sickness Regional Meeting in Juba where the Trypanosomiasis Control policy 
on diagnosis and treatment for the disease was revised in coordination with boarder 
countries (DRC, Congo, Uganda) 
In regard to Tropical Diseases Surveillance, WHO staff initiated the work with the MOH 
regarding the development and implementation of a permanent surveillance system. A 
working group was established and several meetings have been held to discuss the 
“Integrated Disease Surveillance and Responses” model used in several African 
countries in Southern Sudan with a particular emphasis on neglected tropical disease.  
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WHO is also in process of supporting the rehabilitation of a national reference laboratory 
for Tropical Diseases in Juba. In 2006, all the equipment was ordered for the laboratory 
to be usable hopefully in 2007, to verify outbreaks, as Kala azar reference DAT 
laboratory confirmation and for Trypanosomiasis and TB. WHO also supported in 2006 a 
3-month laboratory training for 3 Sudanese laboratory technicians in AMREF Kenya so 
there will be Sudanese local staff to manage the laboratory once rehabilitated. 
 
 
LEISHMANIASIS 
 
Different leishmaniasis entities occur in the Region, each requiring a specific adapted 
control strategy for prevention. Anthroponotic visceral leishmaniasis (AVL) due to 
Leishmania (L.) donovani regularly causes severe outbreaks in Sudan with thousands of 
deaths.  Anthroponotic cutaneous leishmaniasis (ACL) caused by L. tropica is a major 
problem in the Region, particularly in the Syrian Arab Republic  in some urban foci in 
Afghanistan , Iran and Pakistan( . Zoonotic cutaneous leishmaniasis (ZCL) outbreaks 
due to L. major continue to appear periodically in desert zones (in Egypt, Islamic 
Republic of Iran, Iraq, Jordan, Libyan Arab Jamahiriya, Morocco, Pakistan, Syrian Arab 
Republic and Tunisia).  Most of the countries except Sudan, Somalia and Afghanistan ,  
have satisfactory surveillance/case management systems.  
The major challenges regarding these diseases are the absence of evidence based 
validated strategies that allow to prevent or interrupt transmission and the high cost of 
the diagnostic and treatment tools. 
 
Action taken and results achieved: 
  
In 2006, WHO focused on Sudan where hopefully, a cyclic decrease of the yearly 
incidence of cases was noted, reflecting probably the absence of large displacement of 
populations and less introduction of naïve non immunized populations in transmission 
foci.  
Adequate operational support was provided to respond to limited leishmaniasis 
outbreaks , in addition to capacity building activities and rehabilitation to increase 
treatment facilities. In 2006, Seven partners were supplied with free drugs and diagnostic 
tools (dipstick or DAT reagents) .  
More interesting in 2006, was the introduction by Local WHO staff of an innovative 
community based approach to control visceral Leishmaniasis. The health worker manual 
specific for Southern Sudan on community kala-azar (KA) health education which was 
developed by WHO in 2005 was updated and copies produced for distribution for 
trainings organized  with the implementing partners. The field training on community 
awareness was combined with a refresher laboratory training concentrating on the use of 
the dipstick procedure in the diagnosis of kala-azar in peripheral health units, and was 
delivered to NGOs (local and international) partners’ staff. Two PHC units were 
rehabilitated as new treatment facilities, located in Dingkar and Mandeng , to better refer 
patients more appropriately and in a timely fashion. 
 
WHO also contributed to operational support (provision of drugs, diagnostic tools) and 
capacity building in several affected countries of the EMR. and on the development of 
new approaches for the surveillance, prevention and control through operational 
research 
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ZOONOSIS: 
 
Brucellosis and hydatidosis and Rabies remain the major Zoonotic diseases in EMR with 
a considerable economic impact in veterinary and public health sectors. All these 
zoonoses require specific actions/programmes on animals ( animal vaccination, test and 
slaughter, dog deworming etc…) to be prevented or eliminated . This is not happening in 
the majority of the EMR countries because of the absence of comprehensive 
multisectoral programmes, with  products produced by different sectors contributing to 
the same expected result. This is the major challenge. Currently in the EMR countries, 
pathogen surveillance in animals is usually the responsibility of government departments 
of agriculture. Its quality varies greatly among countries and typically (in all countries 
without exceptions) does not include wildlife. In addition, priority diseases supported and 
reported are those of food animals and more particularly those that affect international 
trade.  
 
Action taken and results achieved: 
 
The year 2006, was marked by the adhesion of new member states, who positively 
responded to a call from RD EMRO, to participate in the Mediterranean Zoonoses 
Control Programme , as requested by the resolution adopted in RC50. WHO EMRO also 
pursued close coordination with the MZCP, particularly in regard to the organization of 
common training workshops and meetings with the aim to strengthen   partnership with 
regional and international organizations, such as the World Organization for Animal 
Health (OIE), and the United Nations Food and Agriculture Organization, in order to 
enhance control activities in the region. 
The support of  WHO to countries, included ,capacity building in surveillance and 
management of human cases in selected zoonoses programmes, such as rabies in 
Pakistan and in Yemen. Rabies continues to constitute a major threat , with cases 
reported in 2006 in especially in Pakistan, Afghanistan, Yemen, parts of Iran and 
Palestine. Considerable funds continue to be  spent by most of the countries of EMR 
and WHO-EMRO, in post exposure treatment of humans to  reduce mortality. Morocco 
was supported to assess its actual epidemiological status in regard to hydatidosis and 
the control programme was revised.  
Despite support from WHO and other sources, Pakistan hasn't yet achieved the shift 
from the production of old sheep-brain vaccines to tissue culture vaccines.  
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REGIONAL OFFICE FOR SOUTH-EAST ASIA 
 
<To be inserted SEARO map and list of member states> 
 
 
The South East Asia Region accounts for a disproportionate burden of neglected tropical 
diseases such as leprosy, lymphatic filariasis, kala-azar and yaws. In 2005, the Region 
accounted for 68% of the globally reported new leprosy cases, 65% of the population 
globally at risk of lymphatic filariasis, 20% of the globally reported kala-azar cases and 
about 5000 new cases of yaws.  
“Regional Initiatives for Tropical Diseases targeted for Eradication/Elimination” was an 
agenda item in 59th Meeting of Regional Committee held in Dhaka-Bangladesh in August 
2006. The Regional Committee passed a resolution calling on Member States to give 
high priority to the targeted diseases and increase the allocation of resources. 
 
The Second Meeting of Partners on Tropical Diseases targeted for 
elimination/eradication was successfully held in Jakarta-Indonesia in February 2007, with 
participation from representatives from 21 partner agencies and senior health officials 
from 7 Member States. The meeting was co-sponsored by German Development 
Cooperation (BMZ/GTZ), Global Alliance for Elimination of Lymphatic Filariasis (GAELF) 
and the Sasakawa Memorial Health Foundation-Japan and was able to generate greater 
interest among the participating agencies and a willingness for increased support for 
elimination/eradication efforts. 
 
 
LEPROSY 
 
9 out of the 11 member States have attained the goal of elimination of leprosy as a 
public health problem, leaving only 2 countries – Nepal and Timor-Leste to achieve the 
goal. The Regional prevalence declined from 0.86/10,000 population in 2005 to 
0.79/10,000 population in 2006. In 2006, the prevalence of leprosy has stabilized below 
0.9/10,000 population in India, which traditionally accounted for the highest leprosy 
burden, globally and regionally. 
Of the nearly 15 million cases cured globally with MDT so far, about 12.8 million were 
from the South-East Asia Region, more than 11.8 million of them from India. Thus the 
South-East Asia Region and India have made significant contribution to the reduction in 
the global leprosy burden. 
 
Figure 9. Prevalence Rate per 10,000 population in SEAR countries, September 2006 
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All countries continued to accord high priority to leprosy elimination activities and 
sustained leprosy services within the general health system. In 2006, the annual new 
case detections reduced in most countries, compared to 2005. 
 
Selected country initiatives & success stories  
 
The number cases of leprosy on treatment at the end of 2006 in India dips below 
100,000 for the first time. 
 
Figure 10. Leprosy prevalence in India 1996-2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indonesia, Myanmar and Maldives  
Leprosy Elimination Monitoring (LEM) Exercises were conducted in Indonesia and 
Myanmar and an External Evaluation conducted in Maldives, in order to assess the 
progress of leprosy elimination and quality of leprosy services, including quality and 
supply of MDT drugs. 
 
 
LYMPHATIC FILARIASIS (LF) 
 
The South East Asia Region aims to achieve the Elimination goal by 2015 so that the 
period between 2015-2020 can be utilized for final mop-up and verification exercises.  
The Region accounts for the highest burden of population at risk of LF with nearly 850 
million of 1.3 billion globally at risk. In addition, 50% of the 120 million people with clinical 
manifestations also reside in South East Asia.  
 
      Figure 11. The Global and Regional populations at risk and with infection or disease  
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Mapping for endemicity has been completed in all countries except Indonesia which is 
expected to complete the exercise in 2007.  
 
During 2006, around 100 million people at risk of LF were covered with Mass Drug 
Administration (MDA) with DEC + albendazole in the 9 LF endemic countries of SEAR.   
Maldives, Sri Lanka and Thailand covered their entire endemic population in 2006. 
Timor-Leste is planning to cover the entire endemic population in 2007. Sri Lanka 
completed 5 rounds of MDA, the first country in the region to achieve this milestone. 
 
In July 2006, India, the country with the highest burden of LF globally and regionally,  
announced a policy change and decided to adopt the WHO-recommended 2-drug 
regimen of DEC + albendazole for annual MDA. This will result in rapid scale-up of MDA 
in the country and in the region.  In 2005, India covered only 17 million people in 6 
districts with the 2-drug regimen on a pilot basis and administered DEC alone to about 
537 million people. 
 
The meeting of National LF Programme Managers of the Region was held in Jakarta-
Indonesia 05-07 July 2006. The meeting of South East Asia RPRG was held on 27-28 
April 2006 at Jakarta.    
.  
Selected country initiatives & success stories  
 
Sri Lanka  
 
Sri Lanka’s LF Elimination Programme: 5 rounds of MDA are completed with high 
coverage 
          
 
Figure 12. Sri Lankan nurse distributing albendazole and DEC 
 
• 9.8 million people at risk of LF completed 5 rounds of MDA 2-drug regimen in 
2006;  
• High drug coverage >90% of the eligible population;  
• Microfilaraemia rate now reduced to 0.03%; 
• Used COMBI and social mobilization to enhance compliance; 
• Strong partnerships between Sri Lanka Government, WHO, GlaxoSmithKline, 
            FIFA (Federation for International Football Association), Lymphatic Filariasis  
            Support centre-Liverpool, UK and local NGOs.  
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VISCERAL LEISHMANIASIS (KALA AZAR) 
 
Kala azar caused by parasitic protozoa Leishmania donovani and transmitted by the bite 
of infected female sandfly, Phlebotomus argentipes is predominantly a disease of the 
poorest of the poor.  
In South East Asia Region, the disease is limited to 98 districts in three countries -
Bangladesh, India and Nepal, putting about 200 million people at risk (Figure 
1).  Estimates indicate about 300,000 new cases per year in the Region, which is 8 times 
more than reported..  
During 2005 the reported cases in Bangladesh, India and Nepal were 6891, 28,751 and 
1564 respectively, with Case Fatality rates of 0.28%, 0.54% and 1.34% respectively.  
 
Map 7. Kala-azar endemic areas in the SEA Region, 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is a large gap between estimated cases and the reported cases. Treatment of kala 
azar is hampered by the high cost of drugs. The course of oral drug miltefosine is for a 
period of 28 days, hence high level of patient compliance is required to prevent drug 
resistance. Strict pharmacovigilance including pregnancy register is required since 
miltefosine is potentially teratogenic drug. There is a risk of ongoing transmission 
through Post Kala-azar Dermal Leishmaniasis (PKDL). Control of PKDL is very 
challenging since patients with PKDL have no signs or discomfort.  
 
Following the Memorandum of Understanding(MoU) signed by the Ministers of Health of 
Bangladesh, India and Nepal in May 2005, the political commitment in the three affected 
countries is high and national funds have been allocated for the elimination programme. 
The 3 countries have agreed for joint efforts to eliminate kala-azar as a public health 
problem by 2015. 
 
The Regional Strategic Plan was endorsed at a meeting of partners held in India in 
August 2005. Following the endorsement of the Regional Strategic Plan, the programme 
managers from Bangladesh, India and Nepal prepared the national operational plans for 
implementation in 2006. These were then consolidated into a project document. The 
plan includes a road map for implementation and has identified the resource gaps. Map 
8 shows the pilot districts under implementation in 2006. 
 
WHO has established a Regional Technical Advisory Group (RTAG) to provide technical 
guidance on the elimination of kala azar and will assist the countries in the development 
of technical/operational guidelines. 
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Map 8. Implementation of kala-azar elimination in 2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
YAWS 
 
Yaws is immensely amenable to eradication because it can be easily diagnosed on 
clinical grounds by the health care workers and is fully cured with a single injection of 
long acting penicillin. The disease is geographically confined to small localized foci, 
mainly in remote areas. Historically, use of the strategy of active case finding and prompt 
treatment both of cases as well as family contacts have led to disease eradication. 
Ultimately, Yaws eradication would contribute to reduction of poverty and empowerment 
of a traditional society as nations strive towards achievement of MDGs and at least strive 
towards equitable access to basic health and sanitary conditions. 
 
Based on these arguments, WHO/SEARO has declared Yaws eradication a priority for 
SEA Region and an achievable goal with the target date of 2012.  
 
India  
Due to intensified efforts to eradicate yaws, no cases have been reported in India since 
2004. The country formally declared Elimination of yaws in September 2006 and is now 
conducting sero-surveys in under-5 children and is aiming at Eradication by 2010.  
 
Figure 13. Yaws case detection in India, 1996-2006 
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In Indonesia, every year about 4000 cases are reported from 8-13 of the 30 provinces. 
The number cases provisionally reported in 2006 is around 6,000. Four provinces – East 
Nusa Tenggara, South East Sulewesi, Papua and Maluku account for 95% of the 
annually reported cases There has been a slow-down in the programme implementation 
in the last few years, mainly due to resource constraints. Efforts have to be directed 
towards policy support and greater attention to the effective implementation and 
strengthening of the programme.   
 
In Timor Leste, yaws is considered to be endemic in 6 of the 13 districts. Reliable data 
is not available from the country. An integrated approach is planned, combining 
elimination of lymphatic filariasis, control of soil transmitted helminths and eradication of 
yaws. Such a programme synergy is a novel approach that needs to be supported. 
 
 
Regional Activities 2006 
 
To take the eradication mission forward, WHO has prepared a framework of the 
Regional Strategic Plan and a draft advocacy document for resource mobilization. This 
Regional Strategic Plan 2006-2010 was finalized at a meeting in Bali, Indonesia in July 
2006 and the framework of National Strategic Plans for Indonesia and Timor-Leste  
developed.  
 
The declaration of elimination of yaws in India has motivated Indonesia and Timor-Leste 
to intensify efforts towards implementation of Yaws eradication activities. Both countries 
need additional resources and technical assistance in order to achieve Yaws eradication 
by 2010.  
 
India declares Elimination of Yaws 
 
 
 
 
 
 
SOIL-TRANSMITTED HELMINTHIASIS  
 
Soil transmitted Helminthiasis is a public health problem in all the 11 countries in the 
South East Asia Region. An estimated 500 million of the 1.5 billion people living in these 
countries are believed to be infected while approximately 669,000 DALYs are lost per 
year.  Fig. 1shows the range of STH prevalence rates in the Region.The commonest 
infections include Roundworm (Ascaris lumbricoides), Whipworm (Trichuris trichiura) and 
Hookworm (Necator americanus).  
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Figure 14. Range of STH prevalence rates in the Region 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to achieve the goal of reducing morbidity and mortality caused by soil-
transmitted helminthiasis by 50% and to achieve a target of regular treatment to at least 
75% of all school-age children at risk by 2010, several mass deworming programmes 
have been initiated in the region 
a) Targeting  school-age children through school based approaches integrated with 
school health programmes; 
b) Targeting pre-school children through Integration with Vitamin A supplementation 
programme; 
c) Targeting pregnant and other women through Ante natal care programmes;  
d) Integrating deworming with Mass Drug Administration for LF elimination; 
 
All countries have appointed a national focal point for STH, while 10 countries have 
national deworming policies. Bhutan, Maldives, Sri Lanka, and Thailand  are targeting 
entire high risk school-age population. Bangladesh, Myanmar, Nepal and Timor-Leste 
have plans to expand school deworming programmes in phases to cover entire 
population at risk. DPR Korea, India and Indonesia have prepared their program plans.  
 
Most countries in the Region have developed innovative approaches for integration with 
other activities to rapidly scale up and provide cost-effective interventions: 
• School health programmes (Sri Lanka & Thailand) 
• Vitamin A supplementation programme (Bangladesh & Nepal) 
• IMCI (Bangladesh, Bhutan, Myanmar, Nepal & Timor-Leste) 
• Maternal and Child Health (MCH) programmes (Sri Lanka) 
• Mass drug administration (MDA) for elimination of Lymphatic Filariasis 
• Tsunami health interventions (Indonesia, Maldives, Sri Lanka) 
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Figure 15. WHO–SEARO recruits and networks partners for STH control / elimination 
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<to be inserted WPRO map and list of member states> 
 
 
 
 
Control programmes for Neglected Tropical Diseases (NTD) are currently being scaled 
up in the Region. Institutional donors such as Asian Development Bank as well as the 
United Nations Children's Fund are paying more attention to NTD and a strong political 
commitment is developing in several countries. Most countries have established control 
programmes directed by managers with internationally recognized capacity. The mass 
media and several publications in scientific journals have documented the achievements 
of control methods developed by countries in this Region. A fruitful exchange of visits 
and experiences is taking place within the Region (i.e. visit of the delegation from the 
National Institute of Malariology, Parasitology and Entomology of Vietnam to Cambodia 
during the school deworming campaign, and the exchange visit of Cambodian and Lao 
schistosomiasis control programme managers in border areas endemic for 
schistosomiasis in the two countries). 
 
 
SOIL-TRANSMITTED HELMINTHIASES  
 
The control of soil-transmitted helminths (STH) is being scaled up in the entire Region 
(Figure 1); several countries progressed towards the WHO deworming target of regular 
coverage of 75% of school-age children. The pre-school children risk group is also 
progressively being covered. 
 
Map 9. Comparison of the coverage of school health deworming programmes in some countries 
of the Greater Mekong Subregion in 2002 and 2007 
 
 
2002 2007 
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Selected country activities & success stories  
 
Cambodia 
In 2004, Cambodia was the first country in the world to achieve regular deworming of 
more than 75% of all school-age children. The control programme is covering 2.8 million 
children twice a year and is receiving political and financial support from the government: 
the 2006 campaign was launched by H.E. Mam Bun Heng Secretary of State (Ministry of 
Health) and covered by television, newspaper and electronic media. The involvement of 
high-level personalities of the MoH is indicative of the attention given by the government 
and a positive indication for the long-term sustainability of the activities.    
In addition, approximately 1.3 million pre-school children are covered by deworming 
during the Vitamin A distribution and outreach campaign and the MoH is also planning 
coverage for women of child-bearing age. 
 
China 
Following the results of the national baseline survey conducted in 2004, distribution of 
mass chemotherapy is planned in 2008 in all counties where the infection rate of STH is 
over 30%. In 2007, pilot activities (mass distribution of albendazole) for STH control 
started in 8 counties (1.9 million people covered). In 5 counties albendazole distribution 
is been implemented for 3 years. The total number of people that will be covered in 2007 
is 3 million.  
 
Lao PDR 
The country expects to reach national coverage of school deworming in April- May 2007 
(the target is approximately 1 million children). Financial support of the programme is 
granted by the Luxembourg government until 2008 (see Figure 1). Pilot activities to 
reach pre-school children are being developed. 
 
Pacific Islands 
WHO provided technical support and supported the procurement of deworming tablets in 
Fiji, Solomon Islands, Tuvalu and Vanuatu. The intention is to support the distribution of 
albendazole to school-age children in Pacific islands that have achieved 5 consecutive 
years of albendazole and DEC distribution for the control of lymphatic filariasis (LF) and 
maintain, in this way the health gains obtained in addition to the lymphatic filariasis 
elimination.  
 
The Philippines 
STH are widely transmitted in the country: a recent survey in pre-school children 
demonstrated prevalence between 49 and 92%. The prevalence in school-age children 
is probably higher. Approximately 10 million of children are dewormed every year in the 
Philippines as part of the mass distribution of anthelminthics for the control of LF. 
Another half million were dewormed with support from UNICEF. In order to reach the 
WHO target, an additional 9 million tablets will be necessary.  
An innovative health education tool, the “Urbani Box”, jointly developed with WPRO 
HPR/DHP, is currently pilot-tested in approximately 130 schools in the Philippines 
 
Viet Nam 
Viet Nam is on the way to attain the global target of covering 75% of schoolchildren with 
deworming (6 million schoolchildren will be treated in 2007). The vitamin A and 
deworming campaign will start in June 2007 and cover 1.8 million pre-school children. In 
addition, WHO is conducting a study in collaboration with the University of Melbourne in 
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Yen Bay Province, covering  250 000 women of child bearing age, to evaluate the cost-
effectiveness of weekly iron supplementation and deworming intervention in this group at 
risk. 
 
 
SCHISTOSOMIASIS 
 
Schistosomiasis is not transmitted in the Pacific island countries. The only schistosome 
species transmitted in the WPR are Schistosoma japonicum and S. mekongi. The 
transmission of S. japonicum is confined to China, where schistosomiasis was a major 
problem in eight provinces, and to parts of the Philippines. S. mekongi is transmitted in 
areas along the Mekong River in southern Lao PDR and two adjacent provinces in 
Cambodia. 
 
China 
In 2004, China re-defined schistosomiasis control as one of its priorities in 
communicable disease control, together with control of HIV/AIDS and tuberculosis.  The 
country has adapted endemic classifications and its national control guidelines to the 
current situation, and has set ambitious targets for the next two 5-year periods.  It is 
aimed to have transmission under control by 2008, and to stop transmission by 2015.   
The Ministry of Health has embarked on a 5-year project for schistosomiasis control 
covering the provinces of Anhui, Hubei, Hunan, Jiangsu and Jiangxi, in the lake region, 
and Sichuan and Yunnan in mountainous regions. Mass chemotherapy with praziquantel 
is delivered though the primary health care system and is provided free of charge to the 
populations at risk. In the lake region, control activities are combining distribution of 
praziquantel with environmental modification and replacement of buffaloes with tractors 
in agriculture. 
 
Cambodia  
No schistosomiasis cases were reported in 2006 in Cambodia. This result is particularly 
relevant since  schistosomiasis before was transmitted at a very high level (prevalence 
of infection between 73% and 88%) in the two provinces of Kratie and Stung Treng, 
where approximately 80 000 individuals were at risk of infection. Severe morbidity and 
mortality due to the infection were also very common in the area. In 1994, the Ministry of 
Health of Cambodia started applying universal chemotherapy with praziquantel. The 
coverage of the programme was between 62% and 86% for 8 years. 
The experience in Cambodia demonstrates that with political commitment, parasitic 
disease control is achievable even in situation of minimal resources. The programme 
represents a successful model for other developing countries.  
 
Lao PDR 
Schistosomiasis is transmitted in Champasak province at the border with Cambodia. The 
present epidemiological situation for schistosomiasis in the province is very similar to the 
one of Cambodia in 1996, with prevalence over 60% and several severe cases of severe 
morbidity and mortality. As a result of repeated mass drug administration campaign 
Schistosomiasis was under control in Khong island during the 90’s. The present high 
prevalence is the result of the discontinuation of such campaigns for more than 7 years. 
Praziquantel  in Lao PDR is now available for distribution in 2007. Funds are being 
sought to support a programme similar to the one successfully implemented in 
Cambodia.  
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LYMPHATIC FILARIASIS 
 
Countries and areas in the WPR are making steady progress towards the global goal of 
the elimination of lymphatic filariasis by 2020. For the “Mekong-Plus” countries, China is 
in the final process of verifying interruption of transmission that should be complete in 
early 2007; the Republic of Korea should be also ready for verification for the interruption 
of transmission towards the end of 2007; Brunei needs to carry some final surveys to 
verify that old pockets of transmission are no longer active before starting the verification 
process; while Lao PDR is preparing to implement the final mapping surveys.  Cambodia, 
Malaysia, Viet Nam and the Philippines are actively carrying out annual mass drug 
administration (MDA) campaigns that have achieved high levels of coverage. 
 
Concerning the Pacific countries and areas, PacELF continues to coordinate LF 
elimination. All endemic countries except Papua New Guinea have completed five 
rounds of MDA and are at the critical stage of confirming that prevalence has dropped to 
below the 1% target level. A short term consultant was recruited in October 2006 to 
critically review the PacELF situation; he also provided technical support to the new 
PacELF team leader for reviewing the strategy for this sub-region as well as for further 
developing the survey methodology to assess elimination.  
 
Table 13. MDA for LF elimination in WPRO/PacELF 
Countries  Individuals targeted 
by MDA for LF 
elimination * 
Number of annual MDA 
rounds completed  
 Mean 
coverage  
American 
Samoa 
100 % of eligible 
population (63,308) 
6  61% 
Cook Islands 100 % of eligible 
population (13,572) 
6  81% 
Fiji  100 % of eligible 
population (831,263) 
5  68% 
(mean of 
4 rounds) 
French 
Polynesia 
100 % of eligible 
population (258,709) 
7  97% 
Kiribati 100 % of eligible 
population (93,706) 
5  61% 
Niue 100 % of eligible 
population (1,591) 
5  88% 
Samoa 100 % of eligible 
population (185,234) 
6  72% 
Tonga 100 % of eligible 
population (99,298) 
5 rounds of nationwide 
MDA were completed. 
A target MDA was 
conducted in 2006 in 
Niuatoputapu (coverage 
97%).  
85% 
(mean of 
5 rounds) 
 
Tuvalu 100 % of eligible 
population (9,652) 
5  74% 
Vanuatu 100 % of eligible 
population (221,417) 
5  85% 
Countries 
that 
completed 5 
 round MDA 
Wallis and 
Futuna 
100 % of eligible 
population (15,260) 
5  60% 
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Papua New 
Guinea 
100 % of eligible 
population 
(6,187,108) 
1 province completed 2 
rounds 
 
84% 
(mean of 
1
st
 round) 
Marshall 
Islands 
Residents of Mejit 
island (population 
416, 1999 census) 
and Ailuk atoll (513, 
1999 census) 
3 rounds were completed 
both in Mejit and Ailuk. 
73% 
Countries 
that are 
conducting 
MDA 
Federated 
States of 
Micronesia 
Residents of Satawal 
island (population 
531, 2002 census) 
3  >90% 
(mean of 
2 rounds) 
* Population estimates for 2006 are provided in parentheses. For Marshall Islands (Mrjit and Ailuk) 
and FSM (Satawal), population is based on census. 
 
Table14. MDA for LF elimination in WPR/Mekong-Plus 
 
Country Individuals 
targeted by MDA 
for LF elimination 
Number of annual MDA 
rounds completed 
 Mean 
coverage 
Cambodia 435 000 2  71.3% 
Malaysia 1 170 000 2  67% 
Viet Nam 671 000 4 districts completed 3  
2 districts completed 4  
>80 % 
Countries 
that are 
conducting 
MDA 
Philippines 21 000 000 2-5  68% 
 
 
 
FOOD BORNE TREMATODES 
 
After the workshop conducted in Hanoi in 2003, the control of these neglected diseases 
received new input. Cambodia is completing a mapping of the major FBT with the 
support of researchers from the Korean Association for Health Promotion (KAHP). The 
Lao PDR has already completed mapping and discovered areas of high prevalence of 
Opisthorchis infections; it will start the distribution of praziquantel in Champassak 
province in 2007, combining the control of schistosomiasis and opistorchiasis which both 
are intensively transmitted in the province. 
     
Viet Nam completed the mapping exercise, and developed control plans for each of the 
transmitted food borne trematodes. Personnel of the peripheral health units have been 
trained and control activities started: 10 000 tablets of triclabendazole, the drug of choice 
for fascioliasis, have been donated by WHO and distributed to the district hospitals in the 
areas where fascioliasis cases were reported in the past. Praziquantel will be distributed 
in April 2007 to the entire population of 11 districts in North Vietnam where 
paragonimiasis cases have been identified. 
 
Map 10. Food-borne trematodes in Viet Nam. a) Fascioliasis and b) Pragonimiasis 
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DENGUE 
 
Regional overview of the dengue situation 
Dengue incidence data was available from 19 countries up to 2006. After a particularly 
severe outbreak in 1998 throughout the Region, with 355,063 cases and 1,497 deaths, 
the number of cases and deaths in 1999 decreased sharply (48,122 cases and 255 
deaths) and remained low in 2000 (46,422 cases and 249 deaths). Those figures were 
almost three times higher in 2001 and remained high throughout the period from 2001 to 
2006. However, the overall case fatality rate (CFR) has remained low, under 1.00%, 
since 1998. 
 
Figure 16. Number of dengue cases and case fatality sate from the countries that have data 
available, WHO Western Pacific Region, 1998-2006 
7
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 CFR is calculated based on total number of cases (DF+DHF+DSS) 
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Regional Activities: 
 
In February 2006, WHO Regional Office for the Western Pacific (WPRO) in collaboration 
with WHO Regional Office for South-East Asia (SEARO) and WHO Headquarter 
convened a two-day meeting of partners on dengue prevention and control in Asia-
Pacific in Chiang Mai, Thailand. The objective was to explore the possible concerted 
action towards preventing dengue epidemics. The meeting came up with an agreement 
on setting up a partnership for dengue prevention and control in the Asia-Pacific region. 
The follow-up meeting in February 2007 in Singapore of the Core Group for Asia-Pacific 
Dengue Partnership (APDP) finalized the Strategic Framework and discussed the 
working mechanisms of the APDP. Participants included dengue experts and core 
members from the Western Pacific: Singapore and Tonga and South-East Asia: India 
and Thailand. Also, a draft Strategic Plan for Dengue Prevention and Control in Asia-
Pacific for the period 2007-2015 ) was reviewed and discussed. 
WPRO continues to have limited resources for dengue control and prevention, but 
continues to support surveillance (both routine and rumor surveillance) and outbreak 
response, a number of major community-based vector control activities esp. using the 
COMBI (Communication for Behavioural Impact) methodology, and improvement of 
case-management, whilst seeking to establish a better funding base. 
Thanks to the continued regional advocacy for dengue, the Asian Development Bank 
(ADB) is now providing funds for neglected diseases control including dengue to the 
governments of three Mekong countries (Laos, Cambodia, and Viet Nam) within a 
comprehensive communicable disease control project. The cooperation between WPRO 
and ADB within this project enables WPRO to fund two intercountry staff: one dengue 
(based in Cambodia) and one helminth control expert (based in Laos). In addition, 
USAID has significantly increase their funding for dengue control both at regional and 
country levels (Cambodia, Laos, Viet Nam). 
Most of the reported cases in 2006 were from Viet Nam, Malaysia, Philippines8 and 
Cambodia (Figure 4). In Singapore there was a significant drop in the number of cases in 
2006 compared to 2005 (14,229 and 3,127, respectively). Among the Pacific Island 
countries, Cook Islands, French Polynesia, Fiji, Palau and New Caledonia were facing 
the recurrence of dengue outbreaks. 
 
Figure 17. Number of dengue cases in the countries that have data available, WHO Western 
Pacific Region, 2005 and 2006. 
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 Figure from the Philippines is 10 months only 
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In 2006, there were a total of 481 deaths compared to 749 deaths in 2005. The 
Philippines had the highest number of deaths (244), followed by Cambodia (150), 
Vietnam (68), Malaysia (13) and Lao PDR (6). Although the overall regional CFR in 2006 
was only 0.3%, the CFR in the Philippines and Cambodia were high (1.07 and 0.9, 
respectively) while in Viet Nam, Malaysia and Laos the CFR was low (0.09, 0.04 and 
0.09 respectively). No deaths were reported in Singapore.  
 
Figure 18 Number of deaths in the countries that have data available, WHO Western Pacific 
Regional, 2005 and 20069 
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The Pacific Island countries are specifically vulnerable to dengue epidemics (Figure 6), 
and the impact on the health of its populations and on the economy is massive. An 
economic analysis has been conducted in two countries. An epidemic of dengue virus 
serotype-1 has affected the Pacific in the past years and is ongoing. Early recognition of 
and response to outbreaks are a major challenge. 
 
Map 11. Dengue distribution in Pacific countries, 2001-2004. 
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 The 2005-2006 data are from both official and rumour sources. They will be verified and 
updated when WPRO received all data submitted by member states via official request; 
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New approaches 
 
Several new approaches for dengue prevention and control are being explored in 
dengue endemic countries of the Western Pacific region. In vector control, insecticide-
treated covers are being tested in Cambodia and Laos, where people use concrete jars 
to store water for domestic purposes. It is hoped that this control method can be 
expanded to other countries with similar habitats for Aedes aegypti breeding. Larviciding 
with high coverage levels targeted seasonally to domestic water storage containers in 
large urban areas of Cambodia has proven effective and cost-effective over 5 years. 
Results have been evaluated and are being published. Biological control using 
Mesocyclops is being used successfully in Viet Nam in pilot areas where it is accepted 
by the population. The COMBI approach has been used in Malaysia and Lao PDR; it has 
the potential to bring together different control methodologies based on an assessment 
of the main breeding sites and the risk behaviours of the target population. However, it 
requires capacity strengthening in research and communication as well as significant 
funding.     
 
Country initiatives & success story 
 
Singapore  
The government of Singapore has applied “pro-active" actions in an attempt to eliminate 
dengue mosquito breeding sites with the involvement of communities and different 
sectors and organizations. This will have undoubtedly contributed to the reduction of 
reported cases from 14,229 in 2005 to 3,127 in 2006 but other epidemiological factors 
will also have influenced the decline. 
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PART 3. KEY CHALLENGES FOR EMPOWERING PEOPLE LEFT 
BEHIND TO CATCH UP:  
 
 
We have demonstrated success, but there are two important remaining areas of neglect 
we need to address. 
The first challenge is to generate the resources needed to greatly expand population 
coverage. In this case, success needs to breed much more success. 
Given the power of available interventions to prevent many of these diseases, intensified 
delivery may be the best route to a better life for many millions of people. 
Second, we greatly need research and development for innovative new tools, particularly 
for diseases like African trypanosomiasis, leishmaniasis, and Buruli ulcer. While drug 
donation partnerships offer great hope, it should be noted that many of these drugs were 
already on the market for other indications. 
 
 
Key challenges to be addressed 
 
1. Provision of treatment and other interventions free of charge to communities in need; 
Although the treatment costs per patient for some diseases may be minimal, the total 
costs can be significant given the large numbers affected by neglected tropical diseases. 
Deforming and debilitating diseases may be given high priority by affected populations, 
but impoverished communities cannot afford to cover the costs and their voices are often 
unheard by politicians or policy-makers. External support is needed to provide the 
required interventions in a package to communities at risk at no cost, along the lines of 
childhood immunization. 
 
2. A drug delivery system to cover the whole at-risk population;  
Interruption of transmission through mass drug administration (MDA) requires high 
coverage. Often, however, at-risk populations are not reached as they live in remote 
areas or do not attend schools and are thus missed during school-based campaigns. 
Specific strategies need to be developed to reach these groups and to cover the whole 
at-risk population. 
 
3. Delivery of multi-intervention packages;  
Innovative approaches to add preventive chemotherapy to existing health services 
should be developed. A synergistic approach will streamline operational activities, 
improve efficiencies and ensure that the priority health needs of communities are 
comprehensively met. Packages would need to be offered as a flexible menu of options 
that can be tailored to the local disease situation and adapted to community priorities. 
WHO has a key role to play in putting together technically sound options. 
 
4. Urgent development of diagnostic tools, drugs and pesticides; 
The development of new tools for some neglected tropical diseases belonging to the 
tool-deficient 
category is being addressed within the framework of public–private partnerships. 
However, there is an urgent need for these tools to be made available and also 
accessible to populations in need. 
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5. Production of more effective drugs and insecticides;  
There remains a need to develop new drugs, even for the tool-ready category of 
diseases, in the event of development of drug resistance with the large-scale MDA 
programmes. 
 
6. Promotion of integrated vector management (IVM); 
Efforts are needed to strengthen the infrastructure for integrated vector management, 
embed it in 
existing health services and link it with other sectors (agriculture, irrigation, environment, 
public 
works, information and education). 
 
7. Quantification of the burden of neglected tropical diseases among neglected 
populations;  
Mapping of disease distribution and populations at risk will allow better targeting of MDA 
and other interventions and ensure the efficient use of resources. 
 
8. Early protection of children 
Many of the neglected tropical diseases start early in life, placing children at risk during a 
period of intense physical and intellectual development and further increasing their 
vulnerability to permanent impairment of their human potential. Similar to the principle of 
immunization, whereby children receive early protection against a set of common 
infections according to a schedule of vaccinations and boosters, children can also be 
protected against of set of tropical diseases and their severe manifestations through a 
schedule of early systematic treatments that continue into adult age and make use of 
routine systems and services to ensure sustainability. 
 
9. Post-implementation, surveillance and monitoring.  
Surveillance and monitoring of diseases are fundamental for preserving hard-won 
successes against neglected tropical diseases. Post-implementation surveillance and 
constant monitoring activities should be carried out. Interventions need to be sustained 
over a sufficient time to produce long-term impact and protect new generations from 
infection. 
 
10. Intensifying control of diseases alongside pro-poor policies (advocating an 
intersectoral, interprogrammatic approach to control of neglected tropical diseases;)  
The fight against neglected tropical diseases should form an integral part of pro-poor 
policies. The introduction of basic public health measures, such as primary health care 
services and health education, and improved access to clean water and sanitation, 
would significantly reduce the burden of a number of diseases. 
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 Part 4. A FRAMEWORK FOR ACTION: GLOBAL PLAN TO 
COMBAT NEGLECTED TROPICAL DISEASES 2008-2015 
 
Over the past decades, the World Health Organization (WHO), together with its partners, 
has set a framework for action, Global plan to combat neglected tropical diseases 2008-
2015. Specific aims and targets are defined for the period of 2008-2015 in line with MDG 
and 9 strategic areas have been identified  
 
The strategy encompasses the following components:  
 a multi-pronged approach;  
 focus on populations and interventions rather than specific diseases; 
 use of a quasi-immunization model for preventive chemotherapy; 
 introduction of innovative tools for disease control;  
 a multi-disease, intersectoral and interprogrammatic approach. 
 
Neglected tropical diseases belonging to the “tool-ready” category are those for which 
powerful and inexpensive control tools are currently available and well- developed 
implementation strategies are immediately feasible. Large-scale use of safe and single-
dose drugs (preventive chemotherapy) makes their control, prevention and even 
elimination more feasible than ever before.  
 
The major tasks for control of the tool-ready diseases are to expand coverage of 
packaged preventive chemotherapy interventions, to access the hard-to-reach 
populations at-risk with innovative delivery systems and to continue regular treatment.  
 
Current control strategies for the “tool-deficient” diseases rely on costly and difficult-to-
manage tools. For most of those diseases, early detection and treatment are vital to 
avoid irreversible disability or death.  There is urgent need to develop simple, safe and 
cost-effective tools and make them accessible. Such innovative tools will drastically alter 
the existing control strategies.  
 
The opportunities presented by an intersectoral and inter programmatic approach and its 
successful use in many parts of the globe shows that such a synergistic approach 
improves cost-effectiveness and ensures that all necessary treatments are 
simultaneously delivered to neglected populations, which nearly always suffer from 
several overlapping diseases linked to poverty.  
 
The Global Plan aims at translating this strategy into reality.  
 
 
Principles for action  
 
The Global Plan has been formulated according to the following key principles:   
 the right to health;  
 existing health systems as a setting for interventions;   
 a coordinated response by the health system;  
 integration and equity;  
 intensified control of diseases alongside pro-poor policies.  
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Goal and targets, 2008–2015 
 
The goal of the Global Plan is to prevent, control, eliminate or eradicate NTDs.  
The targets for the plan period 2008–2015 are: 
 To eliminate or eradicate those diseases targeted in resolutions of the World Health 
Assembly and regional committees. 
 To reduce significantly the burden of other tool-ready diseases through current 
interventions. 
 To ensure that interventions with new innovative approaches are available,  promoted 
and accessible for tool-deficient diseases.  
 
Strategic areas for action  
 
The Global Plan comprises nine strategic areas, each of which proposes a series of 
actions to meet specific targets during 2008–2015. The strategic areas are: 
1. Assessment of the burden of NTDs and zoonotic diseases 
2. Integrated approach and multi-intervention packages for disease control 
3. Strengthening health-care systems and capacity building 
4. Evidence for advocacy  
5. Ensuring timely and free access to diagnostic and preventive tools and high-quality 
drugs  
6. Access to innovation  
7. Strengthening IVM  
8. Partnership and resource mobilization  
9. Promoting an intersectoral, interprogrammatic approach to control of neglected 
tropical diseases. 
 
Framework for implementation, monitoring and evaluation   
 
Prior to 2008, a committee will be set up for successful implementation and 
operationalization of the Global Plan.  
Member States, WHO collaborating centres for neglected tropical diseases, other 
relevant international partners and the WHO secretariat will be part of a steering 
committee that monitors implementation and reviews progress.  
 
 
Each WHO Regional Office will develop its own action plans which will fully reflect the 
Global plan to combat neglected tropical diseases 2008-2015 focusing on its prioritized 
diseases.  
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ACRONYMS AND ABBREVIATIONS  
 
AECI   Spanish Agency for International Cooperation  
AFRO  WHO Regional Office for Africa 
AIDS  Acquired immunodeficiency syndrome 
AMRO   WHO Regional Office for the Americas 
BU  Buruli ulcer 
CD  Communicable Diseases, or Communicable Diseases Unit of PAHO 
CDC  Centers for Disease Control and Prevention, Atlanta, USA 
CL  Cutaneous leishmaniasis  
DEC  Diethlycarbamazine 
DNDI  Drugs for Neglected Diseases Initiative 
EMRO  WHO Regional Office for the Eastern Mediterranean 
FAO  Food and Agriculture Organization of the United Nations 
HAT  Human African Trypanosomiasis 
HIV  Human immunodeficiency virus 
IVM  Integrated vector management 
LAC  Latin America and the Caribbean 
LF  Lymphatic filariasis 
LGA  Local Government Area 
MDA  Mass drug administration 
MDT  Multidrug therapy for leprosy 
MOH  Ministry of Health 
MSF  Médecins Sans Frontières 
MZCP  Mediterranean Zoonoses Control Programme 
ND  Neglected diseases 
NID  National immunization day 
NTDs  Neglected Tropical Diseases 
OEPA  Onchocerciasis Elimination Program for the Americas 
PAHEF  Pan American Health and Education Foundation. 
PAHO  Pan American Health Organization. 
PATTEC Pan African Tsetse and Trypanosomiasis Eradication Campaign 
PCC  Program Coordinating Committee of OEPA 
PELF  Programme to Eliminate Lymphatic Filariasis 
PRG  Program review group for LF 
SAFE  Surgery, Antibiotics, Facial hygiene and Environmental improvement for 
trachoma 
SEARO  WHO Regional Office for South-East Asia 
STH  Soil-transmitted Helminths 
TB  Tuberculosis 
TDR  WHO Special Program for Research and Training in Tropical Disease  
UN  United Nations 
UNEP  United Nations Environment Programme 
UNICEF  United Nations Children’s Fund 
USAID  United States Agency for International Development 
VBD  Vector-borne diseases 
VL   Visceral leishmaniasis  
WHA  World Health Assembly 
WHO  World Health Organization 
WFP  World Food Programme 
WPRO  WHO Regional Office for the Western Pacific 
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Annex 1. Selected neglected tropical diseases: description and global burden.  
 
 
Buruli ulcer  
Buruli ulcer is a severe skin disorder caused by Mycobacterium ulcerans. Left untreated, the 
disease progresses to massive destruction of the skin and, in some cases, of bone, eyes and 
other tissues. Permanent disabilities occur in an estimated 25% of cases. Limb amputations may 
be needed to save a patient’s life. These problems are compounded by the dramatic recent 
resurgence of the disease, particularly in parts of west Africa. About 50000 cases of Buruli ulcer 
has been reported from 30 countries mainly in Africa. 
 
Chagas disease  
Chagas disease is a parasitic disease resulting from the bite and subsequent defecation with 
faeces containing the infective stage of this protozoan parasite of the triatomine bug, or “kissing 
bug” in rural areas and periurban slums throughout Latin America. Transfusion of infected blood 
is a second significant mode of transmission. Chronic infection, which usually begins in childhood, 
irreversibly damages the heart, oesophagus, colon and peripheral nervous system in later life. 
Patients with severe chronic disease become progressively ill and ultimately die, usually from 
heart failure and often early in adult life. It is endemic in 21 countries, with 16–18 million persons 
infected and 100 million people at risk.  
 
Dengue and dengue haemorrhagic fever  
Dengue is a mosquito-borne viral infection found in tropical and subtropical regions around the 
world.  
Some 2500 million people – two fifths of the world’s population – in more than 100 countries are 
now at risk from dengue. There may be 50 million  dengue infections worldwide every year. 
South-east Asia and the Western Pacific are most seriously affected.  
Dengue haemorrhagic fever is a potentially deadly complication. It is characterized by high fever, 
haemorrhagic phenomena – often with enlargement of the liver – and, in severe cases, circulatory 
failure. Today, dengue haemorrhagic fever affects most Asian countries and has become a 
leading cause of hospitalization and death among children in several of these countries. Dengue 
is also widespread in several parts of Latin America and the Caribbean. 
 
Dracunculiasis (Guinea-worm)  
Dracunculiasis (guinea-worm disease) is caused by the parasitic worm Dracunculus medinensis 
or “guinea-worm”.  
No medicines are currently available to prevent or heal this parasitic disease – the only disease 
exclusively associated with unsafe drinking-water. Systematic filtering of drinking water is 
effective to eliminate the disease: 168 countries and territories are certified free of guinea-worm 
transmission.  
In 2006, only 10674 new cases of dracunculiasis were reported worldwide; 96% of those are 
concentrated in Ghana, Mali and Sudan.  
 
Human African trypanosomiasis (Sleeping sickness)  
Sleeping sickness threatens 3 millions of people in 36 countries of sub-Saharan Africa. 
Spread by the bite of the tsetse fly, the disease flourishes in impoverished rural parts of Africa.  
Symptoms in the initial phase of the illness, when treatment has the greatest chance of success, 
are often mild or nonspecific. However, patients frequently present for treatment when the 
disease is already far advanced, more complex treatment is needed and the chances of success 
are jeopardized. Untreated, sleeping sickness is invariably fatal. Death follows prolonged agony. 
In 2006, WHO estimated that the disease affects some 70 000 people. 
 
Leprosy 
Leprosy is a chronic disease caused by the bacillus Mycobacterium leprae. M. leprae multiplies 
very slowly and the incubation period of the disease is about five years. Symptoms can take as 
long as 20 years to appear. Leprosy mainly affects the skin and nerves; if untreated, there can be 
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progressive and permanent damage to the skin, nerves, limbs and eyes. Throughout history, the 
afflicted have often been ostracized by their communities and families. However, leprosy is not 
highly infectious and is readily curable. The availability of a highly effective cure – multidrug 
therapy – led to the vision of a world without leprosy. Today, 116 out of 122 endemic countries 
have eliminated leprosy as a public health problem.  
Global registered prevalence of leprosy at the beginning of 2006 was 219 826 cases.  It is still 
endemic in Brazil, Democratic Republic of Congo, Madagascar, Mozambique, Nepal, and United 
Republic of Tanzania. 
 
Leishmaniasis 
Leishmaniasis is a parasitic protozoal disease transmitted by the bite of the sand fly and 
threatens 350 million men, women and children in 88 countries around the world.  
This disease has a wide range of clinical symptoms. Visceral leishmaniasis, which attacks the 
internal organs, is the most severe form. Left untreated, it is usually fatal within two years. The 
cutaneous form usually causes ulcers on the face, arms and legs. Far more devastating is the 
mucocutaneous form, which invades the mucous membranes of the upper respiratory tract, 
causing gross mutilation as it destroys the soft tissues of the nose, mouth and throat.  
The sixth form, recidivans cutaneous leishmaniasis, is a relapsing form that appears after 
treatment. WHO estimates that 12 million people are currently infected, and around 1.5 million to 
2 million new infections occur each year.  
 
Lymphatic filariasis  
Lymphatic filariasis, or elephantiasis, remains silent for a long time after infection that is mostly 
acquired in childhood. The disease is transmitted by mosquitoes that bite infected humans. The 
worms lodge in the lymphatic system, the network of nodes and vessels that maintain the delicate 
fluid balance between the tissues and blood, and are an essential component for the body’s 
immune defence system. The worst symptoms of the chronic disease generally appear in adults, 
and in men more often than in women: damage to the lymphatic system, kidneys, arms, legs or 
(especially in men) genitals causes significant pain, lost productivity on a huge scale and 
discrimination. 
Over 120 million people are currently infected and around 1.3 billion people in more than 80 
countries are at risk of infection. One third of the people infected with the disease live in India, 
one third in Africa and the remainder in South Asia, the Pacific and the Americas. 
 
Onchocerciasis 
Onchocerciasis, or river blindness, is a parasitic disease caused by a filarial worm that is 
transmitted to humans through the bites of black flies that breed in fast-flowing rivers. The 
disease causes severe visual impairment, including permanent blindness, and can shorten the 
life expectancy of its victims by up to 15 years. Other devastating effects of onchocerciasis are 
skin nodules and onchocercal skin disease characterized by skin lesions (severe itching, 
dermatitis, depigmentation, etc.). Severe itching alone is estimated to account for 60% of the 
disease burden.  
More than 100 million people are at risk of infection and some 37 million people are estimated to 
be infected. Over 99% of those affected live in Africa.  
 
Soil-transmitted helminthiasis 
“Helminth” is the technical word for a worm. Soil-transmitted helminths are also known in many 
places simply as common intestinal worms.  
A person infected with soil-transmitted helminths has parasite eggs in his or her faeces. In areas 
where there is no latrine system, the soil (and water) around the village or community becomes 
contaminated with faeces containing worm eggs. The symptoms of soil-transmitted helminth 
infections, which are nonspecific and become evident only when the infection is particularly 
severe, include nausea, tiredness, abdominal pain and loss of appetite. Worm infections 
aggravate malnutrition and amplify rates of anaemia. Approximately 1.6 billion – one sixth of the 
world’s population – is at risk of infection. 
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Schistosomiasis  
Schistosomiasis, one form of which is also known as bilharziasis, is a parasitic disease that leads 
to chronic ill health.  
Humans become infected when they come into contact with contaminated water. A child who has 
suffered persistent and heavy infections is likely to have chronic, irreversible diseases such as 
liver fibrosis, cancer of the bladder or kidney failure, later in life.  
An estimated 70 million people with urinary schistosomiasis in Africa currently suffer from bloody 
urine, indicating damage of the bladder and urinary tract. Forms of schistosomiasis also occur in 
parts of South-East Asia and Latin America and the Caribbean. 
 
Yaws 
Yaws is a contagious, nonvenereal, treponemal infection in humans that presents mainly in 
children younger than 15 years. Peak incidence occurs in children aged 6–10 years. In the 
majority of patients, yaws remains limited to the skin, but early bone and joint involvement can 
occur. Although yaws lesions disappear spontaneously, secondary bacterial infections and 
scarring are common complications.  
After 5–10 years, 10% of untreated patients develop destructive lesions involving bone, cartilage, 
skin, and soft tissue, similar to those seen in tertiary syphilis. In contrast to venereal syphilis, 
cardiovascular and neurological abnormalities almost never occur in patients with yaws.  
Yaws is a significant public health problem in two countries of South-East Asia, and some 
countries in the African and Western Pacific regions. In South-East Asia, about 5000 cases are 
reported annually; 4000 in Indonesia and 1000 in Timor-Leste. India has recently eliminated the 
disease. 
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Annex 2. WHO recommended anthelminthic medicines for use in preventive 
chemotherapy  
 
 
 
Note: Drug names are given in full in the list of abbreviations at the front of the manual. 
a. Prescribing information and contraindications are given in the WHO Model Formulary 2004 
(13 ). 
b. In this table, ✓ indicates drugs recommended by WHO for treatment of the relevant disease, 
and (✓) indicates drugs that are not recommended for treatment but that have a (suboptimal) 
effect against the disease. 
c. At present, LEV and PYR do not have a prominent role in preventive chemotherapy as 
described in this manual. However, they remain useful drugs for the treatment of soil-transmitted 
helminthiasis, and since – unlike ALB and MBD – they do not belong to the benzimidazole group, 
they will be expected to contribute to the management of drug-resistant STH infections should 
that problem emerge. 
d. LEV and PYR have only a limited effect on trichuriasis but, when used in combination with 
oxantel, PYR has an efficacy against trichuriasis comparable to that observed 
with MBD (14). 
 
